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Evaluating the Utility of Clinical Criteria for the Identification of Lynch Syndrome 
among Endometrial Cancer Patients 
 
Amanda S. Bruegl, MD 
Supervisory Professor:  Russell R Broaddus, MD PhD 
 
Background:  Lynch Syndrome (LS) is a familial cancer syndrome with a high prevalence of 
colorectal and endometrial carcinomas among affected family members.  Clinical criteria, 
developed from information obtained from familial colorectal cancer registries, have been 
generated to identify individuals at elevated risk for having LS. In 2007, the Society of 
Gynecologic Oncology (SGO) codified criteria to assist in identifying women presenting 
with gynecologic cancers at elevated risk for having LS.  These criteria have not been 
validated in a population-based setting. 
Materials and Methods:  We retrospectively identified 412, unselected endometrial cancer 
cases. Clinical and pathologic information were obtained from the electronic medical record, 
and all tumors were tested for expression of the DNA mismatch repair proteins through 
immunohistochemistry. Tumors exhibiting loss of MSH2, MSH6 and PMS2 were 
designated as probable Lynch Syndrome (PLS). For tumors exhibiting 
immunohistochemical loss of MLH1, we used the PCR-based MLH1 methylation assay to 
delineate PLS tumors from sporadic tumors. Samples lacking methylation of the MLH1 
promoter were also designated as PLS.  The sensitivity and specificity for SGO criteria for 
detecting PLS tumors was calculated.  We compared clinical and pathologic features of 
sporadic tumors and PLS tumors. A simplified cost-effectiveness analysis was also 
performed comparing the direct costs of utilizing SGO criteria vs. universal tumor testing.  
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Results:  In our cohort, 43/408 (10.5%) of endometrial carcinomas were designated as PLS. 
The sensitivity and specificity of SGO criteria to identify PLS cases were 32.7 and 77%, 
respectively.  Multivariate analysis of clinical and pathologic parameters failed to identify 
statistically significant differences between sporadic and PLS tumors with the exception of 
tumors arising from the lower uterine segment.  These tumors were more likely to occur in 
PLS tumors. Cost-effectiveness analysis showed clinical criteria and universal testing 
strategies cost $6,235.27/PLS case identified and $5,970.38/PLS case identified, 
respectively.   
Conclusions: SGO 5-10% criteria successfully identify PLS cases among women who are 
young or have significant family history of LS related tumors.  However, a larger proportion 
of PLS cases occurring at older ages with less significant family history are not detected by 
this screening strategy.  Compared to SGO clinical criteria, universal tumor testing is a cost 
effective strategy to identify women presenting with endometrial cancer who are at elevated 
risk for having LS.   
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Introduction 
Lynch Syndrome – Definition and Clinic Based Screening Criteria 
 Lynch Syndrome (LS), formerly known as hereditary non-polyposis colorectal 
cancer (HNPCC), is a hereditary cancer syndrome characterized by an elevated 
prevalence of endometrial and colorectal carcinomas, and to a lesser degree other Lynch 
Syndrome associated tumors (LATs), among affected family members.  In 1895, 
pathologist Aldred Warthin at University of Michigan observed a family with a 
significant prevalence of stomach, uterine, and small intestinal tumors.  The male 
proband, whose index cancer was an upper gastrointestinal tumor, had 10 children and 48 
relatives within a three-generation pedigree of which 17 had a diagnosis of cancer during 
their lifetimes (1).  Through his work and subsequent study by Henry Lynch at Creighton 
University, the hereditary cancer syndrome now known as Lynch Syndrome was 
characterized (1,2). 
 The rarity of affected families present in any given region made this syndrome 
difficult for a single investigator to study epidemiology, disease natural history, and 
genetics. In 1990, the International Collaborative Group on Hereditary Non-Polyposis 
Colorectal Cancer, consisting of thirty experts representing eight different countries, met 
in Amsterdam to create criteria for future studies designed to investigate the underlying 
molecular and genetic basis of the disease (3). In 1997, the working group modified the 
Amsterdam criteria to include extracolonic tumors, such as endometrium, stomach, 
ovaries, small bowel, ureter, renal pelvis, brain, and hepatobiliary tract (4).  These 
criteria, summarized in Table 1, ultimately led to the association of LS with germline 
mutations in DNA mismatch repair (MMR) genes.  
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 In addition to the international working group establishing criteria to identify 
individuals with HNPCC, the National Cancer Institute (NCI) also developed criteria to 
address some of the weaknesses in the original Amsterdam Criteria.  These weaknesses 
include the role of extracolonic tumors, probands with small families, and 
clinicopathologic characteristics associated with LS tumors (5).  These criteria, 
summarized in Table 1, were also revised subsequently to include results of molecular 
diagnostic tests such as microsatellite instability testing (6).   
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Table 1. Summary of Amsterdam and Bethesda Criteria for the Evaluation of LS 
 
Amsterdam Ia 
(All criteria must 
be met) 
Amsterdam IIb 
(All criteria must 
be met) 
Bethesdac Revised Bethesdad 
At least 3 relatives 
with CRC, one 
must be a first-
degree relative of 
other 2. 
At least 3 
relatives with a 
LS-associated 
cancer, one 
should be a FDR 
of the other 2 
Proband with 2 LS-
related cancers, 
CRC at age < 50 
FAP has been 
ruled out 
FAP has been 
ruled out 
Proband with CRC and 
an FDR with CRC 
and/or LS-related cancer 
and/or a colorectal 
adenoma; one of cancers 
diagnosed at age <45 or 
adenoma diagnosed at 
age < 40 
Synchronous, 
metachronous or 
other LS related 
tumors 
Two affected 
generations 
Two affected 
generations 
CRC or EC diagnosed at 
age < 45 
MSI-H CRC in a pt 
<60 
At least one of 
CRC cases occurs 
at < age 50 
At least one LS-
associated cancer 
should be 
diagnosed < age 
50 
Right-sided CRC with an 
undifferentiated pattern 
on histopathology 
diagnosed at age < 45  
CRC in ≥ 1 first 
degree relatives 
with an LS related 
tumor, one 
occurring at age <50 
  Individuals with signet-
ring-cell-type CRC 
diagnosed age < 45 
CRC in ≥ 2 first- or 
second-degree 
relatives with LS-
related tumors 
  Individuals with 
adenoma diagnosed at 
age < 40 
 
  Any individual meeting 
Amsterdam Criteria 
 
a:(3)     1: CRC - colorectal cancer 
b:(4)     2: FAP - familial adenomatous polyposis 
c:(5)     3: FDR - first degree relative 
d:(6)      4: EC - endometrial cancer 
     5: MSI-H – microsatellite instability high 
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 Computer-based clinical prediction models emerged in the 2000’s that attempted 
to provide a proband’s individual risk for having a germline DNA MMR mutation.  
These risk calculators include PREMM1,2,6, MMRPredict, and MMRPro (7-9).  For each 
of these models, the original research population consisted of probands presenting with 
CRC and included the model’s ability to predict germline mutations in three of the four 
DNA MMR genes (MLH1, MSH2, and MSH6). The area under the receiver-operator 
curves in the validation studies was greater than 0.8 in each model, indicative of a 
favorable predictor.  These models did not address probands presenting with other LATs 
nor did they evaluate the model’s ability to predict germline mutations in PMS2.  
 Given the favorable results from these results in predicting MLH1, MSH2 and 
MSH6 mutations among probands presenting with CRC, a validation study among EC 
probands was initiated (10).  These prediction models were evaluated using a population-
based cohort consisting of 563 unselected endometrial cancer cases as well as a high-risk, 
clinic-based cohort consisting of individuals from 129 families enrolled in the Colon 
Cancer Family Registry (11).  These 3 prediction models had AUCs < 0.8 in both the 
population-based cohort and high-risk, clinic-based cohorts and were therefore deemed 
less useful tools in the EC population. 
 In 2007, the Society of Gynecologic Oncology (SGO) published a statement on 
risk assessment for inherited cancer syndromes among gynecologic cancer probands (12). 
This expert panel deemed genetic risk assessment for individuals with a 5-10% likelihood 
of having a germline mutation as reasonable and asserted that an individual with a 20-
25% possibility of a germline mutation should undergo risk assessment.  The committee 
published criteria corresponding to the 5-10% and 20-25% risk groups (Table 2).  The 
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20-25% criteria resemble Amsterdam II criteria, and the 5-10% criteria resemble the 
revised Bethesda guidelines. Ryan et al. investigated the performance of these criteria in 
a cohort of 76 EC cases from familial cancer registries at Mount Sinai Hospital and in 
British Columbia with a known LS germline mutation.  The mean age at diagnosis of EC 
in their cohort was 47.3 years, and 28/76 (36.8%) were diagnosed at age greater than 50. 
They found that SGO 20-25% criteria correctly identified 71% of individuals with a 
known LS germline mutation, and the 5-10% criteria correctly identified 93% of 
mutation carriers. The 20-25% criteria best identified MSH2 mutations with a 78% 
detection rate; however, the detection rates for MLH1 and MSH6 were 61% and 50%, 
respectively.  The 5-10% criteria performed equally well in the detection of MLH1 and 
MSH2 mutations and had a detection rate of 94%, but only had an 88% detection rate for 
identifying MSH6 mutations.  There were no known PMS2 mutation carriers in this 
cohort (13). To date, these criteria have not been validated in a population-based setting. 
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Table 2. Society of Gynecologic Oncology (SGO) Criteria for those at 5-10% 
 and 20-25% risk of having a germline mutation in MLH1, MSH2, MSH6, or  
PMS2 (12). 
 
SGO 5-10% Criteria SGO 20-25% Criteria 
EC or CRC diagnosed before age 50 Probands meeting Amsterdam II 
Criteria 
EC or OC with a synchronous or 
metachronous CRC or other LAT at 
any age 
Synchronous or metachronous EC 
or CRC, first cancer occurring 
before age 50 
EC or CRC and a first degree 
relative with LAT diagnosed before 
age 50 
Synchronous or metachronous OC 
or CRC, first cancer occurring 
before age 50 
EC or CRC and ≥ 2 first or second 
degree relatives with LATs 
CRC or EC with tumor testing 
suggestive of LS (IHC or MSI-H) 
Proband with first or second degree 
relatives who meet these criteria 
First or second degree relative with 
a known germline mutation 
 EC: Endometrial Cancer   LAT: Lynch Syndrome associated tumor 
 CRC: Colorectal Cancer   MSI-H: Microsatellite Instability-High 
 OC: Ovarian Cancer   IHC: Immunohistochemistry
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 Published data suggest that women with EC and mutations in PMS2 and MSH6 
are often older with less extensive family histories of CRC or other LATs (14,15).  In a 
study by Goodfellow et al., endometrial cancers were evaluated in a population-based 
fashion to characterize the role of MSH6 mutations in endometrial cancer.  In their cohort 
of  441 unselected endometrial cancer cases an MSH6 mutation was identified in 1.6% 
(7/441). The median age at diagnosis for these carriers was 53.6 years (range: 45-71), and 
5/7 cases occurred after age 50 (16).  
 Bonadona et al. evaluated cancer risk in a cohort of 537 LS germline mutation 
carriers enrolled in the French Estimation des Risques de Cancer chez les porteurs de 
mutation des genes MMR (ERISCAM) study.  The LS cases in this cohort consisted of 
248 MLH1, 256 MSH2 and 33 MSH6 mutation carriers.  In their examination of the 
lifetime cancer risks for MSH6 carriers, they found that the cumulative risk for 70 years 
of age for CRC was 12%, EC 21%, ovarian cancer 1% and 0% for stomach, small bowel, 
and biliary tract.  These risks are substantially lower that of MLH1 and MSH2 mutation 
carriers.  Data from this study show that individuals with LS and an MSH6 mutation have 
less overall risk for cancer compared to MLH1 and MSH2 mutation carriers (15). Much 
of the data we have regarding LS and EC is extrapolated from CRC registries, which tend 
to be dominated by MLH1 and MSH2 mutations.  It is not clear if such data can be 
applied to MSH6 mutation carriers, who have a distinct cancer risk profile.  Thus, we may 
be underestimating and under-diagnosing the number of women with EC and LS.  
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Lynch Syndrome Associated Tumors (LATs) 
 In addition to CRC and EC, other Lynch Syndrome associated tumors (LATs) 
have been identified that occur in germline mutation carriers at higher rates than that of 
the general population.  These LATs include ovary, gastric, small intestine, hepatobiliary 
tract, urinary tract, brain and skin (17). For women with germline mutations, the lifetime 
risks of EC and CRC are 39.4% and 42.7%, respectively.  The risk of developing either 
EC or CRC is 73.4% (18).  Additionally, women with germline mutations are at least 
equally as likely to present with a gynecologic cancer as their sentinel cancer diagnosis as 
they are CRC (19).   
DNA Mismatch Repair (MMR) 
 DNA replication is a process in which errors occur at a rate of 1 of every 104 
nucleotides. DNA polymerase, an enzyme essential to the replication process, has an 
innate proofreading ability which improves the fidelity of DNA replication to 1 in 106 
(20). In addition to intra-replicative error repair, there also exist other repair systems that 
address errors persistent after DNA replication has been completed.  The DNA MMR 
system identifies and repairs mismatches in nucleotide pairs following DNA replication.  
Figure 1 summarizes the overall process for this system.  Following an error in 
replication, the MSH2/MSH6 heterodimer recognizes and binds to a base-pair mismatch.  
MLH1/PMS2 proteins are recruited, which in turn, recruit Exonuclease 1.  The 
mismatched base-pair is excised and DNA polymerase inserts the appropriate base-pair in 
to the sequence (21).  Germline mutations in the DNA MMR repair genes, MLH1, MSH2, 
MSH6 and PMS2, are the genetic basis for Lynch Syndrome.  
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Figure 1.  Schematic representation of DNA MMR system. 
              A. Nucleotide mismatch occurs 
              B. MSH2/MSH6 heterodimer surveys DNA, recognizes error, and                      
                   initiates MMR process 
              C. MLH1/PMS2 are recruited, DNA polymerase is displaced from  
       DNA strands, exonuclease is recruited and mismatched pair  
       is removed 
                          D. DNA polymerase returns and resynthesized DNA with correct  
         strand 
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Molecular Diagnostic Tools In the Evaluation for Lynch Syndrome 
Tissue-based Screening Methods: Microsatellite Instability, Immunohistochemistry, and 
MLH1 methylation   
 Tissue-based LS screening assays emerged in the 1990s, providing another 
clinical tool in identifying individuals who should proceed with germline testing.  DNA 
microsatellites consist of multiple, tandem repeats of mono-, di-, and tri- nucleotides; 
such repeats are prone to errors during the DNA replication process.  Errors in DNA 
replication resulting in a change in the number of tandem repeats is termed microsatellite 
instability (MSI) (22).  The Bethesda Panel is a published set of microsatellite sites 
recommended for PCR-based MSI analysis.  An earlier panel included BAT-25, BAT-26, 
D5S346, D2S123 and D17S250, with subsequent recommendations to add BAT40 and 
TGF-βR2 (6).  Using the panel of 7 microsatellites, a tumor exhibiting allelic shift in 3 or 
more markers is designated as MSI-high (MSI-H), 1-2 markers is MSI-low (MSI-L), and 
no allelic shift is microsatellite stable (MSS).  Lynch Syndrome associated cancers are 
typically MSI-H, while sporadic tumors with no defects in DNA MMR are typically 
MSS.  MSI-L represents somewhat of a clinical conundrum (23).  Nearly all MSI-L 
colorectal carcinomas are sporadic.  However, a substantial subset of endometrial 
carcinomas from women known to have Lynch Syndrome mutations are MSI-L or MSS 
(Am J Path 2002 reference emailed to you Sat morning).   
 In addition to MSI analysis, the development of monoclonal antibodies against 
DNA MMR proteins has allowed IHC to become another technique available in 
evaluating for LS.  Tumors with positive nuclear expression of these proteins typically 
have an intact MMR system.  Loss of protein expression in tumor cell nuclei with 
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preserved stromal cell staining is suggestive of LS.  Individuals with mutations in MLH1 
will typically have IHC loss of MLH1 and PMS2, while patients with MSH2 mutations 
will have IHC loss of MSH2 and MSH6, due to the dominant role of MLH1 and MSH2 
in heterodimer formation of the MMR complex. Individuals with germline mutations in 
MSH6 or PMS2 typically show only IHC loss of the corresponding MMR protein (24,25). 
 Approximately 15-20% of all endometrial and colorectal adenocarcinomas have 
epigenetic silencing of the MLH1 promoter secondary to methylation (26-28).  Between 
65-96.9% of endometrial tumors exhibiting MLH1 loss have methylation at the MLH1 
promoter region (29-32).  By performing this PCR-based assay as part of the LS 
evaluation, unnecessary and costly genetic testing can be avoided.  Despite the 
availability of this assay, it is not universally utilized in published clinical studies (33-
36).  One reason is that PCR-based technology may not be as readily available in all 
pathology laboratories, whereas performance of IHC is fairly straightforward, less 
expensive, and more universally available. 
Performance of MSI and IHC 
 The utilization of MSI or IHC to aid in the evaluation for LS varies across 
different institutions based on resources and departmental standards.  A recent study by 
Bartley et. al examined the concordance/discordance between MSI and IHC in patients 
undergoing tumor testing in the evaluation for LS (37).  The majority of tumors evaluated 
were colorectal adenocarcinomas (88%), with a smaller fraction of endometrial 
adenocarcinomas (7%).  They found an overall concordance of MSI and IHC results in 
97.8% of tumors.  
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 The overall sensitivity of MSI and IHC analyses for identifying LS germline 
mutations in CRCs is similar, with rates of 83% and 94%, respectively (38).   The slightly 
decreased sensitivity of MSI is attributed to MSH6 and PMS2 mutations, which more 
often tend to be associated with MSS and MSI-L tumors (39,40). 
BRAF and Endometrial Cancer 
 In colorectal cancers, 5-10% of sporadic, MSI-H tumors will be associated with a 
mutation in the BRAF gene, a component of the MAPK pathway (41).  The prevalence of 
this mutation in CRCs has made BRAF analysis a component of standard tumor testing in 
evaluation CRCs for LS.  In particular, BRAF mutation analysis may be useful in patients 
with CRCs with IHC loss of MLH1, when an MLH1 methylation assay is not available.  
BRAF mutations are exceedingly rare in EC (30,34,42), so this test has not been 
incorporated into the clinicopathologic algorithms for LS evaluation in EC patients. 
Pathologic Features Associated with Lynch Syndrome 
 There are certain pathologic features in EC that have been shown to be associated 
with LS tumors.  These features include tumors arising from the lower uterine segment 
(LUS), tumors with peritumoral lymphocytes, and presence of tumor infiltrating 
lymphocytes (43,44).  LUS tumors are a relatively rare phenomenon, occurring in only 
3.5% of all endometrial adenocarcinomas; however, the prevalence of LS in this subset of 
patients is 29% (44).  The presence of peritumoral lymphocytes, lymphocytes 
surrounding a tumor at scanning power microscopically, has an odds ratio of 2.8 in 
predicting PLS tumors (43).  Similarly, tumor infiltrating lymphocytes (TILs) are 
aggregates of lymphocytes located within the tumor and have an odds ratio of 3.1 in 
predicting PLS tumors (43). 
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 A study investigating the value of young age and the pathologic features of 
peritumoral lymphocytes, TILs and heterogeneous tumors (tumors consisting of 2 
histologies with each contributing at least 10% to tumor volume) in identifying DNA 
MMR defects was performed by Garg et al.  Individuals who were either younger than 50 
years of age, had any of the aforementioned pathologic findings, or whose primary 
physician requested tumor screening were included in their analysis.  Their study found 
that utilizing age and these features improved detection of tumors that correlated with 
DNA MMR defects (45). It should be mentioned here that endometrial carcinomas with 
these unique features (young age of diagnosis, heterogeneous histology, LUS anatomic 
location, and TILs) can indeed be associated with Lynch Syndrome.  But, because 
population-based studies are lacking, it is less certain whether the majority of Lynch 
Syndrome-associated endometrial carcinomas have these unique features. 
National Recommendations of Ideal Screening Strategy for LS 
 In 2009, the Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) Working group (EWP) published their recommendations regarding LS 
screening among CRC patients.  They placed less emphasis on using family history as an 
initial triage tool, recommending that all patients with CRCs undergo evaluation for LS in 
the form of MSI and/or IHC testing and (46).   The reasoning behind the removal of 
family history resulted from several factors.  First, Amsterdam II and Revised Bethesda 
criteria, both heavily dependent on utility of family history, have far from optimal 
sensitivity or specificity. Next, obtaining an accurate family history often requires a 
skilled professional such as a genetic counselor. This requires both time and clinical 
resources in addition to patient compliance.  Finally, these criteria work less well for 
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patients from small families or in scenarios in which the family history of cancer is not 
known.  Although the working group removed family history as a requirement, it did not 
deter the health care team from utilizing this information as part of the full evaluation for 
LS. 
  A recent publication from the Cleveland Clinic evaluated three universal tumor 
testing regimens and found the approach that led to the best detection rate and follow up 
was universal testing in which the surgeon and genetic counselor both played lead roles 
in patient notification and follow-up (47).  A national consensus on the ideal method of 
screening for LS among EC patients is not available.  While the publication of SGO 
criteria helped to define the likelihood of identifying a Lynch Syndrome mutation in 
women with EC, this group did not provide recommendations on methods of patient 
screening. 
Germline Testing 
 The traditional “gold standard” for diagnosing LS is to perform sequencing to 
detect a known germline mutation in one of the DNA MMR genes.  This involves 
sequencing of the coding region of the gene and, in the case of PMS2, the performance of 
multiplex ligation-dependent probe amplication (MLPA) to detect mutations in the PMS2 
pseudogene.  Mutations in MMR genes are not in hot spots, as is the case for KRAS or 
BRAF mutations.  Sequencing has excellent sensitivity for detecting point mutations and 
minor insertions and deletions, but accurate detection of large deletions, insertions or 
gene rearrangements is a limitation of conventional sequencing technology (48).  It is 
unclear whether individuals with molecular diagnostic testing results (IHC loss of MMR 
protein, MSI-H) suggestive of LS with negative germline testing are truly negative for 
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Lynch Syndrome or if their mutations have genetic features that make identification by 
conventional sequencing methods difficult.  This is a controversial topic in the field of 
Lynch Syndrome research. 
Cancer Prevention for Individuals with Lynch Syndrome 
 After the time of sentinel cancer diagnosis, an individual has a cumulative 1.5-3% 
yearly risk of developing a second LAT (49).  The identification of LS at the time of 
sentinel cancer diagnosis allows for heightened cancer screening in the individual as well 
as testing and appropriate screening of first degree relatives (FDRs).  Heightened CRC 
screening, via colonoscopy every 1-2 years, decreases the incidence of CRC among 
individuals with LS by 62% (50).  The ideal methods of screening for endometrial and 
ovarian cancers are not known, but many experts agree that yearly evaluation of the 
endometrial cavity with endometrial biopsy and/or transvaginal ultrasound is a reasonable 
approach.   
 Women with known germline mutations may elect to undergo prophylactic 
hysterectomy and/or bilateral salpingo-oopherectomy to reduce their risk of developing 
endometrial or ovarian cancer.  A study by Schmeler et. al compared gynecologic cancer 
outcomes among germline mutation carriers between those who did and did not undergo 
prophylactic surgery. Findings showed a 33% incidence of EC among those who were 
managed expectantly compared to 0% in the prophylactic surgery group.   Incident cases 
of ovarian cancer were too small to determine statistical significance (51). 
Costs Associated with Screening Strategies 
 There are ample data supporting effective identification of patients with LS and 
prevention of subsequent cancers in both affected individuals and primary tumors in first 
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degree relatives (FDRs).  The concept of cost analysis to ascertain the benefit of various 
health strategies emerged in the 1990s as a tool to assist in determining the best treatment 
and prevention strategies both in terms of clinical effectiveness as well as cost 
effectiveness. 
 Four different subtypes of cost analysis exist: cost minimization analysis, cost 
effectiveness analysis, cost utility analysis, and cost-benefit analysis.  Cost minimization 
analysis is perhaps the simplest evaluation, comparing strategies of equal effectiveness to 
determine which is the least expensive.  Cost effectiveness analysis compares alternative 
strategies for a specific condition or disease and evaluates both cost and outcome.  Cost 
utility analysis incorporates mortality and morbidity into alternative strategies being 
compared, utilizing quality adjusted life year (QALY) as its metric of measurement.  
Lastly, cost-benefit analysis compares alternative strategies with different effectiveness 
and different costs (52).  These strategies are often employed utilizing computer-based 
algorithms based on large cohorts of hypothetical patients.  Assumptions are then placed 
into the model based on published literature and individual analysis inclusion criteria. 
 Regardless of the type of analysis used for a study, there are three key elements at 
the foundation of any economic healthcare study. First, define the approaches being 
compared, such as standard of care vs. a new strategy for a disease treatment.  Second, 
the perspective of which we are basing costs relays whether this is from the viewpoint of 
the patient, hospital/care provider, or society.  Lastly, the outcome(s) being measured 
should be clearly defined.  This can be either very broad or quite focused in nature 
depending on the goals of the study (52). 
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 In response to the recommendations by the EWG in 2009 that all CRCs should be 
offered laboratory evaluation of their tumors, Mvundura et al. investigated the cost 
effectiveness of such an initiative and compared it to age-targeted testing (testing all 
cases occurring before age 50).   The strategies being compared were: 1) IHC testing for 
all DNA MMR proteins with genetic sequencing based on IHC results for those with loss 
of MSH2, MSH6 or PMS2 and those with loss of MLH1 with negative BRAF testing; 2) 
IHC testing for all DNA MMR proteins and IHC directed genetic sequencing for those 
with loss of any protein type; 3) MSI testing of all tumors with gene sequencing for all 
MSI-H tumors; and, 4) genetic sequencing of all tumors.  They utilized a decision model 
involving 150,000 hypothetical patients.  The costs accounted for in this study were those 
associated with identifying LS for each strategy as well as the costs associated with 
genetic counseling, genetic testing, surveillance for CRC, and complications of 
colonoscopy for both the individual and his/her first-degree relatives.  The outcome 
measure was both discounted life-years (LY) saved and quality-adjusted life years 
(QALY).  The authors concluded that the most effective economic strategy was Strategy 
1 (53).  
 Kwon and colleagues initiated a similar study in EC to evaluate the cost-
effectiveness of several different screening strategies.  They used a Markov Monte Carlo 
simulation model to perform a cost analysis comparing six different models for detecting 
LS in EC.  The strategies compared were: 1) those meeting Amsterdam II criteria; 2) 
women aged younger than 50 at diagnosis with at least one first degree relative (FDR) 
with an LAT; 3) IHC of all women aged younger than 50 at diagnosis with targeted 
germline testing based on IHC results; 4) IHC of all women aged younger than 60 at 
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diagnosis with targeted germline testing; 5) IHC for any woman with at least one FDR 
had an LAT; 6) IHC of all EC cases.  The incremental cost effectiveness ratio (ICER) 
was the metric used to compare these groups; it is “the additional cost of a specific 
strategy divided by its health benefit compared with an alternate strategy”(33).  In 
general, an ICER of $50,000 per QALY or less has been arbitrarily accepted as a cost-
effective strategy (54).  They found that IHC triage of women with EC who had 1 FDR 
with an LAT was the most favorable screening strategy with an ICER of $9,126 per year 
of life gained (33).
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Hypothesis and Specific Aims  
The absence of population-based evaluations of SGO 5-10% clinical criteria in 
the endometrial carcinoma literature has prompted us to investigate its performance in an 
unselected cohort of EC patients.   These criteria parallel the Bethesda Guidelines, which 
were derived from data from colorectal cancer registries.  Given the fact that these 
guidelines are extrapolated from CRC patient data, we hypothesize that SGO 5-10% 
criteria (which will be referred to as SGO Criteria from this point on) will fail to identify 
a majority of LS patients in the EC population. 
Specific Aim 1.  Evaluate the performance of SGO Criteria in detecting 
 individuals at elevated risk for LS in endometrial cancer.  
 A1)  Calculate the sensitivity and specificity of SGO Criteria in  
         identifying probable Lynch Syndrome (PLS) EC cases in a   
          convenience sample in which molecular testing has already been  
           performed.   
A2)  Determine the number of individuals who meet MDACC institutional  
screening criteria who actually receive referrals for genetic 
counseling. 
 B)   Calculate the sensitivity and specificity of SGO Criteria in an  
                   unselected, sequential cohort of EC cases in identifying PLS cases. 
 
 
 
 
  
 
20
Specific Aim 2. Determine if clinicopathologic features distinguish  
sporadic EC from PLS EC. 
 A)   Determine if historical risk factors of LS such as low BMI, young age 
         at diagnosis and strong family history are significantly different  
         between sporadic EC and PLS EC cases. 
 B)  Compare clinicopathologic characteristics between sporadic and PLS  
       EC cases to determine if alternative clinical screening criteria exist. 
 C)  Determine the utility of MLH1 methylation analysis in the evaluation  
        of endometrial carcinomas with IHC loss of MLH1. 
Specific Aim 3.  Perform a simplified cost-effectiveness analysis comparing 
direct costs of utilizing a clinical history-based model, SGO Criteria, to a 
universal tumor testing model (immunohistochemistry and MLH1 methylation 
analysis when  indicated). 
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Methods 
Institutional Approval 
 This study received Institutional Review Board Approval by the University of 
Texas, MD Anderson Cancer Center IRB (PA12-0131). 
Patient Population 
 Convenience Cohort 
 350 EC patients were identified who had previously undergone IHC 
analysis for DNA MMR protein expression at MD Anderson Cancer Center, with 
complete clinicopathologic information available for 337. The majority in this 
cohort, 149 (44.2%), were from a protocol in which EC cases were selected based 
solely on matched frozen tumor tissue availability (55).  Fifty-five EC cases came 
from a study evaluating the prevalence of LS among women diagnosed with EC 
prior to age 50, a risk factor known to increase an individual’s risk for having LS 
(56).  An additional 52 cases were derived from a study that evaluated women 
with synchronous endometrial and ovarian cancers, an indicator in Revised 
Bethesda guidelines for tissue testing for LS (57). Fifty-one cases were obtained 
from a study evaluating the concordance between MSI testing and IHC in LATs, 
with most of these patients recruited based on young age and family history of 
LATs (37).  An additional 17 patients were obtained from a study investigating 
the association of LS and LUS tumors (44). The remaining 13 EC patients were   
known to have LS germline mutations. 
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Unselected, Sequential Cohort 
 Using a Department of Pathology database, we identified patients 
diagnosed with endometrial cancer between 2004-2011 who had undergone 
surgery at the University of Texas, MD Anderson Cancer Center. EC cases were 
included if the woman was 18 years of age or greater, surgery was performed at 
MD Anderson Cancer Center, and sufficient tissue was available for molecular 
analysis.  All histotypes of endometrial carcinoma were included.  Selection was 
not based on historical risk factors for LS such as young age at diagnosis or 
family history. 
 Genetic Counseling Referral Cohort 
 To assess the genetic counseling referral process, we retrospectively 
reviewed clinical and pathologic data for endometrial cancer cases at MD 
Anderson Cancer Center between 2007-2010.  Patient clinical history was 
obtained from the electronic medical record.  At the time of this analysis, 
institutional referral criteria were as follows: 1) any patient with a history of CRC; 
2) any patient with an FDR with CRC or EC; 3) any patient with a relative of any 
degree with EC or CRC diagnosed before age 50; or 4) any patient with relatives 
who have a known LS germline mutation. Patients were classified as either 
“meets criteria for genetic counseling referral” or “genetic counseling referral not 
warranted.”  Then, genetic counseling referrals were charted for each patient in 
the “meets criteria” category. 
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Data Collection 
  Clinical data were extracted from the electronic medical record (EMR).  Data 
recorded included race/ethnicity, age at EC diagnosis, age of menarche and menopause, 
gravidity/parity, history of cancer, history of any hormone replacement therapy, BMI 
(kg/m2), past medical history of diabetes/hypertension/thyroid disease, family history of 
cancer, and total number of first-degree relatives (FDRs). 
 Tumor characteristics were derived from pathology reports generated by 6 
gynecologic pathologists. Recorded pathologic data included: tumor histology, tumor 
location (corpus/LUS), tumor grade, surgical stage, largest tumor dimension (cm), depth 
of invasion, and presence of lymph-vascular space invasion (LVSI). 
Immunohistochemistry 
 Immunohistochemical analyses for the nuclear protein expression of MLH1, 
MSH2, MSH6, and PMS2 were performed on sections from formalin-fixed, paraffin-
embedded endometrial carcinomas.  IHC was performed using standard techniques for 
MLH1 (G168-15, 1:25; BD Biosciences Pharmingen), MSH2 (FE11, 1:100; 
Calbiochem), MSH6 (44, 1:300; BD Biosciences Pharmingen), and PMS2 (Alb-4, 1:125; 
BD Biosciences Pharmingen (37,57).  A tumor exhibiting nuclear loss of protein 
expression by light microscopic examination was designated as negative for that MMR 
protein.  The presence of nuclear staining in surrounding stromal and normal tissues 
served as internal positive controls (Figure 2).   
  
 
          Figure 2A and 2B.  
MMR protein expression
nuclei and stromal cell nuclei in (A) and 
nuclear staining in (B) without presence of tumor staining.
 
Example of IHC retention (A) and loss (B) of 
. Non-nuclear staining of both tumor cell 
retention of stromal cell 
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MLH1 Methylation 
For cases in which there was IHC loss of MLH1 protein expression, PCR-based 
MLH1 promoter methylation analysis was performed. DNA was isolated from formalin-
fixed, paraffin-embedded tissue sections that were microdissected with a scalpel blade to 
provide relatively pure tumor samples for analysis. Isolated DNA was treated with 
bisulfite to convert methylated cytosine to uracil.  The treated DNA was then amplified 
using fluorescently labeled PCR primers that were specific for methylated (M) or the 
unmethylated (U) versions of MLH1 (MLH1-M forward, 5_-gatagcgatttttaacgc-3_ and 
MLH1-M reverse, 5_-tctataaatactaaatctcttcg-3_; MLH1-U forward, 5_-
agagtggatagtgatttttaatgt-3_ and MLH1-U reverse, 5_-actctataaattactaaatctcttca-3_).  
Amplified PCR products were then detected using capillary electrophoresis and 
GeneScan software.  Chromatograms for tumor were compared to those generated for the 
RKO colon carcinoma cell line (positive control known to have loss of MLH1 protein 
due to MLH1 promoter methylation) and the leukemia cell line K562 (negative control 
with no MLH1 methylation) (Figure 3) (57).  
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Figure 3. For cases with IHC loss of MLH1, PCR-based MLH1 promoter 
methylation analysis was performed. Rows 1 and 2 are negative and positive 
controls, respectively. Row 3 and 4 show normal and tumor tissue from the same 
patient, respectively. The absence of a second peak in the normal tissue and presence 
of a second peak in the tumor indicates methylation of the MLH1 promoter in the 
tumor.  
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Definition of Probable Lynch Syndrome (PLS) and Sporadic EC Tumors 
 Tumors with intact IHC nuclear staining for all 4 DNA MMR proteins and those 
with MLH1 loss and MLH1 promoter methylation were designated sporadic tumors.  
Tumors with absent nuclear staining for MSH2, MSH6 or PMS2 were designated as PLS.  
Tumors exhibiting MLH1 loss with absence of MLH1 promoter methylation were also 
designated as PLS.   
Statistical Analysis 
 Statistical analyses were conducted using SAS software, version 9.2 (SAS, Inc. 
Cary, NC).  Clinical and pathological criteria were compared across a variety of groups.  
Fisher’s, chi-squared, Mann-Whitney, or t-test were conducted to test association across 
groups depending on the distribution of the data. CART analysis was performed to 
attempt to select a set of variables that would predict Lynch Syndrome, but none of the 
models were good fits.  Sensitivity and specificity were also calculated for SGO Criteria 
in its ability to predict PLS EC tumors in both the convenience sample cohort and 
unselected, sequential cohort. 
Cost-effectiveness Analysis 
 The cohort of 412 unselected, sequential EC cases was used to perform a 
simplified cost-effectiveness analysis.  The direct costs of utilizing SGO Criteria were 
compared to universal tumor testing (IHC and MLH1 methylation analysis when 
indicated) of all EC tumors. Effectiveness was expressed in two ways: 1.) the number of 
women with EC in which PLS was identified, and 2.) the total number of women with EC 
in which PLS was identified as well as identification of LS in their FDRs.  Both technical 
and professional costs were collected for genetic counseling visits, IHC for the 4 DNA 
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MMR proteins, MLH1 promoter methylation assay for tumors with IHC loss of MLH1, 
and single gene germline testing.  The cost of single site genetic testing was used for 
identification of mutations in FDRs. 
 Cost analyses were performed using both institutional costs and Medicare 
reimbursement fees.  MDACC institutional cost data were provided by the Department of 
Clinical Revenue and Reimbursement for specific procedure codes (CPT codes) derived 
from a review of billing records and CPT codes.  Table 3 shows a list of items and costs 
included in these analyses.  Medicare reimbursement figures were obtained from the 
Physician Fee Schedule and Laboratory Fee Schedule 
(http://www.cms.gov/Medicare/Medicare-Fee-for-Service-
Payment/PhysicianFeeSched/index.html). All cost amounts are shown in 2012 US 
dollars. 
 In the SGO Criteria model, the original 412 EC cases were stratified according to 
whether or not they fulfilled SGO 5-10% criteria and only those tumors meeting criteria 
underwent further work-up with IHC for DNA MMR proteins, MLH1 methylation when 
indicated, and genetic counseling.  In the universal tumor testing model, all 412 EC cases 
underwent IHC following hysterectomy, and PLS patients underwent genetic counseling 
and germline testing.  
 
  
 
29
Table 3.  Unit costs included in screening strategies (expressed in 2012 US dollars)1 
 
 
MDACC 
institutional   
costs 
Medicare 
reimbursement 
amounts 
   
Initial genetic counseling 
consultation (1 hr) a $264 $210 
   
Follow-up genetic counseling 
visits (30 min)b $132 $104 
 
IHC for MLH1, MLH2, 
MSH6, and PMS2 c 
 
$349 $422 
MLH1 promoter methylation 
assay for tumor with IHC 
loss of MHL1 d 
$316 $125 
   
Single gene germ-line 
testing2 $1300 $1300 
   
Single site testing3,4 $475 $475 
 
1 Includes technical and professional components  
2 Cost of germline testing was obtained from Myriad ABN worksheet 
3
  Cost of single site testing was obtained from Myriad ABN worksheet 
4
  Single site testing intended for first degree relatives of pts with endometrial cancer who 
were identified as having Lynch Syndrome based upon positive germline test results 
a
 MDACC costs derived from CPT code 96040 in 2010 billing statements and converted to 
2012 US dollars.  CPT 99215 and CPT 99213 were used to determine Medicare 
reimbursement amounts from the 2012 Fee Schedule. 
b  Costs adapted from CPT code 99214.  
c
 CPT code 88342 used for each individual IHC DNA MMR protein 
d
 CPT codes 83900, 83909, 83912 from 2012. 
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  The following assumptions were made for the cost effectiveness analysis: 1) 
women with PLS would all be willing to undergo genetic counseling and recommended 
germline testing; 2) women identified as PLS by SGO Criteria had an average of 5.3 first 
degree relatives and women identified as PLS by universal tumor testing had an average 
of 5.5 first degree relatives (these numbers were extracted from the electronic medical 
record); 3) all FDRs recommended to undergo screening and testing would be compliant.  
 Finally, to evaluate the impact on the incremental cost per additional case of 
Lynch Syndrome identified, we varied our assumptions regarding the proportion of FDRs 
who would have positive germline tests (e.g. single-site test based upon initial germ line 
mutation found in women with PLS) from 25% to 75%.  These estimates of 25%, 50%, 
and 75% are based on the variable rate at which immunohistochemistry is found to 
predict germline mutations (48,58).  The incremental cost-effectiveness ratio (ICER) is 
an estimate of the cost per unit of effectiveness of different screening strategies.  We 
varied the percentages of FDRs we assumed would test positive, between 25%-75%, to 
evaluate how cost-effectiveness ratios would differ based on these assumptions within a 
given strategy.  The ICER is calculated as the difference in costs between alternative 
screening strategies divided by the difference in effectiveness between screening 
strategies (Figure 4). 
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Figure 4.  Equations used to derive the ICER for SGO (comparing SGO to no 
intervention) and ICER for Universal tumor testing (UTT) (comparing UTT to SGO 
criteria costs).  Effectiveness is the number of PLS cases identified.
Incremental Cost Effectiveness Ratio (ICER)SGO = 
SGO Criteria Costs – Baseline Costs 
SGO Effectiveness – Baseline Effectiveness 
Incremental Cost Effectiveness Ratio (ICER)UTT= 
UTT  Costs – SGO Criteria Costs 
UTT Effectiveness – SGO Effectiveness 
  
 
32
Results 
Aim 1A1. Performance of SGO Criteria in a Convenience Sample of EC Cases 
 Three-hundred-and-fifty cases of endometrial cancer were identified that had 
previously undergone immunohistochemical analysis for DNA MMR protein expression at 
MD Anderson Cancer Center, and complete clinicopathologic information was available for 
337 (Figure 5).  There was an average of 5.3 FDR per PLS case identified.  
 In this cohort, 56/337 (16.6%) were PLS EC tumors.  IHC loss of MLH1/PMS2 with 
unmethylated MLH1 occurred in 14/56 (25%), loss of MSH2/MSH6 in 24/56 (42.8%), loss 
of MSH6 only in 11/56 (19.6%) and loss of PMS2 only in 7/56 (12.5%). The median BMI of 
all PLS cases was 32.0, and median age at diagnosis was 49.  
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Figure 5. Immunohistochemical and MLH1 methylation results for a convenience sample of 
350 Endometrial Cancer Cases. 
 
EC: endometrial cancer 
IHC: immunohistochemistry 
PLS: probable Lynch Syndrome 
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Promoter 
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Unmethylated 
MLH1 Promoter 
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 Sensitivity and specificity of SGO Criteria were 76.8% and 44.4%, respectively. For 
EC cases meeting SGO Criteria, mean age at diagnosis was 48 years, mean BMI was 33.6, 
17.7% had a family history of EC and 46.9% had a family history of CRC.  Tumor location 
in the lower uterine segment (LUS) was in 25.6% of these cases. In the 43/56 PLS cases 
meeting SGO Criteria, IHC loss of MLH1/PMS2 occurred in 11, MSH2/MSH6 in 21, MSH6 
only in 7, and PMS2 only in 4. 
 Of the 13 (23.2%) patients not captured by clinical criteria, mean age was 68 years, 
mean BMI 34.4, no cases had a family history of CRC and one patient had a first-degree 
relative with a gynecologic cancer of unknown origin. EC cases missed when employing 
SGO screening criteria were associated with IHC loss of MLH1/PMS2 in 3, MSH2/MSH6 in 
3, MSH6 only in 4, and PMS2 only in 3 instances.  Tumor arising from the LUS occurred in 
33.3% of these cases.  If LUS tumors were made a component of SGO Criteria, sensitivity 
and specificity in this cohort become 85.7% and 40.2%, respectively. 
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AIM 1A2. Number of individuals meeting MDACC Criteria Referred for Genetic Counseling 
 Between 2007-2010, 1064 endometrial cancer patients new to MDACC were seen in 
the gynecology oncology clinic.  Of these, 156 (14.7%) met institutional guidelines for 
referral to a genetic counselor to assess risk for LS.  Forty-nine of these patients (30.2%) 
received a recommendation to see a genetic counselor (Figure 5).   Of the 107 EC patients 
meeting criteria but not referred to genetic counseling, a large number had compelling 
personal or family histories of cancer.  One EC patient had a prior history of CRC, 57 had a 
FDR with CRC (5 diagnosed at less than age 50), and 29 had a FDR with EC (3 diagnosed at 
less than age 50).  Six EC patients had a FDR history significant for both EC and CRC.  
Additionally, only 12/30 EC patients who had a second degree relative with an LAT 
diagnosed before age 50 received a referral. 
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Figure 6. Referral experience of endometrial cancer patients who meet MDACC 
Gynecologic Oncology Center Genetic Counseling Criteria for Lynch Syndrome evaluation 
from 2007-2010. 
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Aim 1B. Performance of SGO Criteria in an unselected cohort of EC cases 
 From the results of the convenience sample study in Aim 1A1, it was noted that a 
substantial subset of PLS patients were older than age 50 and/or did not have compelling 
family histories of CRC or EC.  Therefore, we hypothesized that LS screening in a 
population-based fashion would identify patients who would otherwise not be identified 
when screening is based on historical risk factors.  Four hundred twelve consecutive, 
unselected EC cases met inclusion criteria and underwent molecular testing (Figure 7). There 
was one case in which immunohistochemistry and three cases in which MLH1 methylation 
were unsuccessful.  Of the 411 cases with complete IHC results, 118 had loss of at least one 
MMR protein (90 MLH1/PMS2, 12 MSH2/MSH6, 9 MSH6 and 7 PMS2). Of those with loss 
of MLH1/PMS2, 72/90 (80%) had methylation of the MLH1 promoter (Figure 7).  The total 
number of PLS EC cases in our series was 43 (10.5%).  There was an average of 5.5 FDRs 
per PLS EC case identified in this cohort. 
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Figure 7. IHC and MLH1 methylation results of the unselected, sequential cohort of EC 
cases.
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 Demographic and pathologic information for this cohort is summarized in Table 4. 
The median age at diagnosis was 60.5 with a range of 18-92.  Most patients were of white 
ethnicity, older than age 50 years, obese (BMI ≥ 30 kg/m2), and had unremarkable family 
histories for EC or CRC.  The median tumor size was 4.3 cm.  Most tumors were 
endometrioid histology, low grade, early stage, and located in the corpus.  
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     Table 4.  Demographic and pathologic data for 
      the cohort of unselected, sequential EC cases. 
 
Characteristic Number (%) 
Race 
    White 
     Non-White 
 
270  (66.2) 
138  (33.8) 
Age (years) 
     < 50 
     ≥ 50 
 
62   (15.2) 
346 (84.8) 
History of Any Cancer 
     Yes 
     No 
 
53 (13.0) 
355 (87.0) 
Synchronous Tumor (any type) 
     Yes 
     No 
 
27 (6.6) 
381 (93.4) 
BMI (kg/m2) 
     < 30 
     ≥ 30 
 
138 (33.9) 
269 (66.1) 
History of Diabetes 
     Yes 
     No 
 
98 (24.0) 
310 (76.0) 
Family History of EC 
     Yes 
     No 
 
39 (9.8) 
360 (90.2) 
Family History of CRC 
     Yes  
     No 
 
66 (16.5) 
335 (83.5) 
Histology 
     Endometrioid 
     Non-endometrioid 
 
336 (82.4) 
72 (17.6) 
Grade 
     1&2 
     3 
 
299 (73.3) 
109 (26.7) 
Stage 
     I & II 
     III & IV 
 
326 (79.9) 
82 (20.1) 
Tumor Location 
     Corpus 
     Lower Uterine Segment 
 
395 (96.8) 
13 (3.2) 
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 The sensitivity and specificity of SGO Criteria and its associated 95% confidence 
intervals are 34.1% (20.5, 49.9) and 77.6 % (72.9,81.8), respectively.  The sensitivity of SGO 
Criteria by type of IHC loss is presented in Table 5.  SGO Criteria perform best in patients 
with tumors exhibiting IHC loss of MLH1/PMS2 or MSH2/MSH6 and perform poorly in 
tumors with IHC loss of only MSH6 or PMS2. 
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Table 5. Sensitivity and specificity of SGO Criteria in identifying PLS EC cases.  
 
 Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Probable Lynch Syndrome 
(N = 43) 
 
32.6 
(19.1 – 48.5) 
77.2 
(72.7 – 81.6) 
MLH1/PMS2 
 (N = 15) 
 
40.0 
(16.3 – 67.7) 
--- 
MSH2/MSH6  
(N = 12) 
 
42.7 
(15.2 – 72.3) 
--- 
MSH6  
(N = 9) 
 
22.2 
(3.0 – 60.0) 
--- 
PMS2  
(N = 7) 
 
14.3 
(0.3 – 57.9) 
--- 
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 Ninety-seven of 408 (23.8%) of all EC cases fulfilled SGO Criteria.  Of these, 14/97 
(14.4%) were PLS EC tumors based on tissue testing and 83/97 (85.6%) that would be 
characterized as sporadic based on tissue testing. This also results in 29/43 (67.4%) PLS 
tumors that did not meet criteria that would go undetected in a clinical screening criteria 
based referral system. 
 For the 43 patients identified by tissue testing as PLS, the patterns of IHC loss 
between those that do and do not meet SGO Criteria were examined (Figure 7).  Tumors with 
IHC loss of MLH1 and MSH2 were the predominant types of PLS tumors among those that 
fulfill SGO Criteria (11/14).  Among those failing to meet criteria (n=29), there is a fairly 
equal distribution of types of IHC protein loss.  IHC loss of MLH1/PMS2 occurred in 9, 
MSH2/MSH6 in 7, MSH6 only in 7, and PMS2 only in 6. 
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Figure 8. Type of IHC protein loss for EC cases do (A) and do not (B) meet SGO Criteria. 
 
  
A 
B 
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 Select clinical and pathologic characteristics between those that do and do not meet 
clinical criteria were further investigated (Table 6).  Those patients meeting SGO Criteria had 
a younger age at diagnosis, stronger family history of EC and CRC, and a higher frequency 
of tumors arising from the lower segment than those who do not meet criteria.  Regardless of 
whether or not criteria are met, the majority of PLS EC cases do not have a family history of 
EC or CRC. 
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Table 6.  Features of EC patients who do and do not meet SGO Criteria. 
 
Total PLS 
 
N = 43 
Meets SGO Criteria 
 
N = 14 
Does Not Meet SGO 
Criteria 
N = 29 
Median age at diagnosis 48.5 63.0 
Average BMI (kg/m2) 32.0 33.0 
Family History of EC1 2/14 (14.3%) 2/29 (6.9%) 
Family History of CRC2 4/14 (28.6%) 4/29 (13.8%) 
LUS Tumor3 3/14 (21.4%) 2/29 (6.9%) 
 
1EC,  endometrial cancer    
 
2CRC, colorectal cancer    
 
3LUS, tumor arising from lower uterine segment 
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Specific Aim 2A. Evaluation of Historical LS risk factors 
 Young age at cancer diagnosis is one of two fundamental characteristics present in 
published clinical screening criteria for LS. Our data show that 62/408 (15.2%) of all EC  
occurred in patients younger than 50 years of age.  Of these 62 cases, 10/62 (16.1%) were 
PLS tumors, and 10/43 (23.2%) of all PLS tumors occurred in this age category.  Thus, 75% 
of PLS cases in this cohort occur at older ages.  Figure 9 shows the distribution of EC cases 
by age.  The median age at diagnosis is 61 years for both sporadic EC and PLS EC groups.  
The age range for patients with sporadic tumors is wider (18-92) than for PLS (42-87). PLS 
cases did not occur at less than age 40, whereas sporadic EC occurred as young as 18 years.  
After age 40, the proportion of individuals with PLS or sporadic EC at any age is similar. 
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 Figure 9.  Distribution by age of EC cases for all EC tumors, sporadic tumors, and  
 PLS tumors. 
Age (Years) 
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 The other fundamental characteristic of published screening criteria is a strong family 
history of EC or CRC.  Less than 30% of EC patients in this cohort had a family history of 
either EC or CRC.  Table 7 shows the family histories of EC, CRC and either EC or CRC for 
the sporadic and PLS EC groups.  Family history of these cancers does not distinguish 
sporadic from PLS.   
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       Table 7.   Family history of EC, CRC, and EC or CRC in sporadic and PLS EC cases        
       in the unselected, sequential cohort. 
  
Family History Sporadic EC  
N (%) 
PLS EC 
N (%) 
p-value 
EC 35 (9.8) 4 (9.8) > 0.99 
CRC 58 (16.2) 8 (19.0) 0.63 
EC or CRC 87 (24.2) 12 (28.6)  0.54 
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Specific Aim 2B. Comparison of clinicopathologic features in PLS and Sporadic EC to 
determine if alternative screening criteria exist 
 Clinicopathologic characteristics were compared between the sporadic and PLS 
patients in our sequential, unselected cohort (Table 8).  With the exception of tumors arising 
from the lower uterine segment (LUS), there was no statistically significant difference 
identified between these two groups.  Although not statistically significant, there was a trend 
toward younger age at diagnosis (23.3%), lower BMI (39.5%), personal history of 
hypertension (58.1%) and smaller tumor (3.6 cm) among the PLS EC cases. 
 From the complete list of all clinicopathologic data collected, a Classification and 
Regression Tree (CART) analysis was performed to determine if more ideal screening 
criteria could be generated that could effectively delineate sporadic from PLS EC tumors.  
This analysis yielded no superior criteria.   
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     Table 8.  Comparison of clinical and pathologic features between sporadic and PLS EC  
     cases. 
 
Clinical Features Sporadic EC 
N (%) 
PLS EC 
N (%) 
p -value 
Age (years) 
     < 50 
     ≥ 50 
 
52 (14.2) 
313 (85.8) 
 
10 (23.3) 
33 (76.7) 
 
0.12 
BMI (kg/m2) 
     < 30 
     ≥ 30 
 
121 (33.2) 
243 (66.8) 
 
17 (39.5) 
26 (60.5) 
 
0.41 
History of Diabetes 
     Yes 
     No 
 
89 (24.4) 
276 (75.6) 
 
9 (20.9) 
34 (79.1) 
 
0.62 
History of Hypertension 
     Yes 
     No 
 
201 (55.1) 
164 (44.9) 
 
18 (41.9) 
25 (58.1) 
 
0.10 
Pathologic Features Sporadic EC 
N (%) 
PLS EC 
N (%) 
p -value 
Histology 
     Endometrioid 
     Non-endometrioid 
 
299 (81.9) 
66 (18.1) 
 
37 (86.0) 
6 (14.0) 
 
0.67 
Stage 
     I & II 
     III & IV 
 
289 (79.2) 
76 (20.8) 
 
37 (86.0) 
6 (14.0) 
 
0.42 
Grade 
     1 & 2 
     3 
 
267 (73.2) 
98 (26.8) 
 
32 (74.4) 
11 (25.6) 
 
0.86 
Depth of myometrial invasion 
     < 50% 
     ≥ 50% 
 
257 (70.4) 
108 (29.6) 
 
32 (74.4) 
11 (25.6) 
 
0.85 
Tumor Location 
     Corpus 
     Lower uterine segment 
 
357 (97.8) 
8 (2.2) 
 
38 (88.4) 
5 (11.6) 
 
0.007 
Largest tumor dimension (cm) 
     Mean 
     Median 
 
4.3 
4 
 
3.6 
3.5 
 
0.13 
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  Next, a receiver-operator curve (ROC) was generated in which age was varied within 
the SGO Criteria by 1-year intervals (Figure 10).  Ideally, the area under the curve is 0.8 or 
greater.  Varying age does not improve the sensitivity and specificity profiles of SGO 
Criteria.  Increases in sensitivity come at the cost of decreases in specificity.   
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Figure 10.  Receiver-operator curve (ROC) depicting SGO Criteria with age criteria being 
varied in 1–year intervals. 
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 Finally, clinicopathologic variables for the different types of PLS were compared 
(Table 9).  There is a trend toward younger median age at diagnosis between those exhibiting 
MSH2/MSH6 loss and PMS2 loss only; however, the age range is fairly similar across all 
types of MMR deficiency types.  There were more individuals with a BMI (kg/m2) < 30 and 
no family history of EC in these two groups as well.  However, overall, there were no 
clinicopathologic variables that distinguished any of these groups.
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Table 9.  Comparison of clinicopathologic characteristics by MMR deficiency type. 
 MLH1/PMS2  
No methylation 
N = 15 
MSH2/MSH6 
N = 12 
MSH6 
N = 9 
PMS2 
N = 7 
p-value 
 
Median age 
at diagnosis 
 
(Range) 
 
 
62 
 
 
(43-79) 
 
56 
 
 
(42-71) 
 
62 
 
 
(50-76) 
 
56 
 
 
(45-87) 
 
0.50 
 
 
--- 
BMI < 30 
 
8 (53%) 10 (83.3%) 8 (88.9%) 2 (28.6%) 0.30 
FH EC1 
 
 3 (21.4%) 0 1 (12.5%) 0 0.31 
FH CRC2 
 
3 (20%) 3 (25%) 1 (12.5%) 1 (14.3%) 0.95 
LUS3 Tumor 
 
1 (6.7%) 1 (8.3%) 0 3 (42.9%) 0.05 
Endometrioid 
Histology 
 
13 (86.7%) 9 (75%) 8 (88.9%) 7 (100%) 0.62 
Stage I & II 
 
13 (86.7%) 8 (66.7%) 9 (100%) 7 (100%) 0.14 
Meets SGO 
Criteria 
6 (40.0%) 5 (41.7%) 2 (22.2%) 1 (14.3%) 0.62 
 
1EC, endometrial cancer 
2CRC, colorectal cancer 
3LUS, tumor arising from lower uterine segment 
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Specific Aim 2C. Utility of MLH1 Methylation Analysis among EC with MLH1 IHC loss 
 Most EC with MLH1 IHC loss are sporadic secondary to MLH1 methylation rather 
than familial due to MLH1 mutation.  We investigated whether any clinical or pathological 
features can reliably distinguish the MLH1 IHC negative (sporadic) and MLH1 IHC negative 
(PLS) endometrial cancer patients. Utilizing the convenience sample of 337 EC cases, IHC 
loss of MLH1 nuclear expression was detected in 54/337 (16%) of endometrial tumors.  Of 
these, 40/54 (74.1%) endometrial tumors demonstrated MLH1 promoter methylation and 
were designated as sporadic endometrial carcinomas.  The remaining 14/54 (25.9%) lacked 
MLH1 methylation and were designated as PLS.  The proportion of MLH1 methylated 
tumors is comparable to that seen in several other studies consisting of unselected 
endometrial cancer patients with a range of 65-96.9% (Figure 11) (29-32).   
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Figure 11.  Results of IHC for MLH1 and MLH1 methylation in convenience sample  
cohort of EC cases.
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 Clinical and pathologic characteristics for the endometrial cancer patients with and 
without MLH1 promoter methylation are shown in Table 10.  There was no statistical 
difference between median age of diagnosis, median body mass index (BMI), or family 
history of CRC or EC between the MLH1 methylated and unmethylated promoter groups.  A 
personal history of diabetes was statistically more common in the unmethylated group.  
 Investigation of tumor-specific characteristics revealed no statistically significant 
differences between the two groups with respect to histology, FIGO stage, endometrioid 
grade, lymphatic/vascular space invasion, tumor location, or tumor size (Table 10).  Depth of 
myometrial invasion was the only pathologic characteristic that was statistically different 
between the two groups.  Deep myometrial invasion was seen in 37.5% of MLH1 methylated 
tumors, whereas 71.4% of the MLH1 unmethylated tumors had myometrial invasion greater 
than or equal to 50% myometrial thickness.  In this cohort, 25/54 of the patients had 
endometrial carcinomas with depth of myometrial invasion greater than or equal to 50% total 
myometrial thickness making this a criterion of low specificity. 
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Table 10.  Patient and tumor characteristics for EC in the convenience sample cohort with 
IHC loss of MLH1, stratified by presence or absence of MLH1 promoter methylation. 
 
 
Methylated MLH1  
n (%) 
Unmethylated MLH1  
n (%) 
P - value 
Patient Characteristics 
Age 
     Median age at diagnosis 
     Age range 
 
57 
31-92 
 
52 
42-79 
 
0.4295 
Median Body Mass Index 
     <30 
     ≥ 30 
32.9 
13 (33.3) 
26 (66.7) 
30.9 
5 (35.7) 
9(64.3) 
> 0.999 
Family History of EC1 4 (10.5) 3 (21.4) 0.370 
Family History of CRC2 7 (18.4) 3 (21.4) 0.999 
Diabetes 4 (10) 6 (42.9) 0.013 
Hypertension 23 (57.5) 6 (42.9) 0.371 
Tumor Characteristics 
Histology 
     Endometrioid 
     Non-Endometrioid 
 
35 (87.5) 
5 (12.5) 
 
11(78.6) 
3(21.4) 
 
0.413 
FIGO Stage3 
     I & II 
     III & IV 
 
27 (67.5) 
13 (32.5) 
 
11 (78.6) 
3 (21.4) 
 
0.515 
Endometrioid Tumor Grade 
     1 or 2 
     3 
 
26 (74.3) 
9 (25.7) 
 
9 (81.8) 
2 (18.1) 
 
 
> 0.999 
Median depth of myometrial 
invasion (mm)4 
     < 50% myometrial invasion 
     ≥ 50% myometrial invasion 
 
9.0 
25 (62.5) 
15 (37.5) 
 
9.5 
4 (28.5) 
10 (71.4) 
 
0.487 
0.035 
Lymphatic/vascular space 
invasion  
24 (60.0) 8 (57.1) > 0.999 
Tumor location 
     Corpus 
     Lower uterine segment 
 
37 (92.5) 
3 (7.5) 
 
11 (78.6) 
3 (21.4) 
 
0.173 
Tumor Size  
     < 4 cm 
     ≥ 4 cm 
 
21 (52.5) 
19 (47.5) 
 
8 (57.1) 
6 (42.9) 
 
> 0.999 
1EC, endometrial cancer 
2CRC, colorectal cancer 
3FIGO stage I and II denote endometrial carcinomas confined to the uterus.  FIGO stages III   
 and IV represent extra-uterine spread of tumor. 
4Depth of myometrial invasion ≥ 50% total myometrial thickness is associated with increased   
 risk of lymph node metastasis. 
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The sensitivity and specificity of various clinical screening criteria and selected 
patient characteristics are presented in Table 11.  Young age of EC diagnosis was included 
here, as this is a common feature included in many different clinical screening criteria for LS.  
BMI less than 30 was also included, because it has been previously reported that endometrial 
cancer patients with LS have a lower BMI than patients with sporadic endometrial cancer 
(56).  Single factors such as young age, BMI less than 30, family history of colorectal cancer, 
and family history of EC showed poor overall sensitivity and specificity in ability to predict 
MLH1 methylation status accurately. The SGO criteria had a moderate sensitivity (71.4%) 
and specificity (69.2%).  Amsterdam II criteria had a high specificity, 94.9%, at the expense 
of sensitivity, only 14.3%.  When the statistically significant factors from Table 10, deep 
myometrial invasion and patient history of diabetes, were added to SGO 5-10% criteria, 
sensitivity increased to 100%, but specificity was low at 35.9%. Overall, SGO 5-10% criteria 
had the best sensitivity and specificity profile of the screening criteria evaluated in this cohort 
of EC cases.  
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  Table 11.  Sensitivity and specificity of selected clinical characteristics and    
   screening criteria in predicting presence or absence of MLH1 methylation  
  in endometrial carcinomas with MLH1 loss by immunohistochemistry 
 
 Sensitivity Specificity 
Age < 50 50.0 77.5 
Body mass index < 30 33.3 35.7 
History of diabetes 42.8 90.0 
Myometrial invasion > 50% 71.4 62.5 
Family history colorectal cancer 21.4 81.6 
Family history endometrial 
cancer 
21.4 89.5 
Amsterdam II Criteria 14.3 94.9 
SGO Criteria 71.4 69.2 
SGO Criteria or ≥ 50% 
myometrial invasion or diabetes 
100 35.9 
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 Since SGO Criteria performed the best in this cohort, we sought to further examine 
clinicopathologic features of the 4 EC cases not captured by the criteria. Table 12 presents 
patient clinical and pathologic characteristics of the 4 EC cases lacking MLH1 promoter 
methylation (PLS) that were not captured by SGO criteria (in other words, 4 patients 
designated as sporadic endometrial cancer rather than PLS endometrial cancer). In each case, 
patients are older than age 50 years, have a body mass index greater than 30, and there is no 
family history of CRC.  One patient has an LUS tumor, and all but one of the patients had 
deep myometrial invasion.
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Case Age at EC 
Diagnosis1 
BMI DM2 Family 
History of 
EC 
Family 
History 
of 
CRC3 
Meets 
Amsterdam 
II Criteria 
Tumor 
Location 
(Corpus 
or LUS4) 
 
FIGO
Stage 
Tumor
Grade 
Tumor 
Size (cm) 
Histology5 Depth of 
Uterine 
Wall 
Invasion  
1 61 51.8 No Cousin 
age > 50 
No No Corpus II 1 13 E > 50% 
2 64 30.9 No No No No LUS II 1 3 C > 50% 
3 71 38 Yes Mother 
unknown 
gyn cancer 
age > 50 
No No Corpus IA 2 5.5 M < 50% 
4 79 31 Yes No No No Corpus IIIC2 2 1.9 E > 50% 
 
Table 12.  Characteristics of EC cases with immunohistochemical loss of MLH1 and absence of MLH1 methylation (PLS) that were 
incorrectly designated as sporadic by SGO criteria 
 
   
1EC, endometrial cancer 
2DM, diabetes mellitus 
3CRC, colorectal cancer 
4LUS, tumor arising from lower uterine segment  
5E, endometrioid carcinoma; C, clear cell carcinoma; M, mixed endometrioid and sarcomatoid carcinoma 
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 Given these findings in the convenience sample cohort, these characteristics were 
also evaluated in the population–based cohort (Table 13).  As in the convenience sample 
cohort, there was no statistically significant difference between the clinical characteristics 
of median age of diagnosis and family history of EC or CRC.  The significant association 
of diabetes between unmethylated and methylated MLH1 found in the convenience 
cohort was not present in the population-based cohort.  This suggests that the statistically 
significant difference found in the convenience sample may be due to Type I error.  
Investigation of tumor-specific characteristics revealed no statistically significant 
differences between the two groups with respect to histology, FIGO stage, endometrioid 
grade, lymphatic/vascular space invasion, tumor location, median tumor size or depth of 
myometrial invasion.    The statistically significant difference of deep myometrial 
invasion found among unmethylated tumors in the convenience sample cohort may be a 
result of Type I error or the inherent biases of the endometrial cancer cases used to 
generate the convenience sample. 
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Table 13. Patient and tumor characteristics for EC in the consecutive, unselected cohort 
with IHC loss of MLH1, stratified by presence or absence of MLH1 promoter 
methylation. 
 
 
Methylated MLH1  
n (%) 
Unmethylated MLH1  
n (%) 
P - value 
Patient Characteristics 
Age 
     Median age at diagnosis 
     Age range 
 
63 
49-92 
 
62 
42-79 
 
0.235 
Age 
     < 50 
     ≥ 50 
 
1 (1.4) 
71 (98.6) 
 
4 (26.7) 
11 (73.3) 
 
0.003 
Family History of EC1 5 (7.1) 3 (21.4) 0.123 
Family History of CRC2 5 (7.0) 3 (20.0) 0.140 
History of Diabetes 16 (22.2) 6 (40.0) 0.192 
Meets SGO Criteria 6 (8.5) 6 (40.0) 0.005 
Tumor Characteristics 
Histology 
     Endometrioid 
     Non-Endometrioid 
 
70 (97.2) 
2 (2.8) 
 
13 (86.7) 
2 (13.3) 
 
0.136 
FIGO Stage3 
     I & II 
     III & IV 
 
57 (79.2) 
15 (20.8) 
 
13 (86.7) 
2 (13.3) 
 
0.725 
Endometrioid Tumor Grade 
     1 or 2 
     3 
 
59 (81.9) 
13 (18.1) 
 
12 (80.0) 
3 (20.0) 
 
 
> 0.999 
Median depth of myometrial 
invasion (mm)4 
     0 mm 
     < 50% myometrial invasion 
     ≥ 50% myometrial invasion 
 
 
10 (13.9) 
41 (56.9) 
21 (29.2) 
 
 
3 (20.0) 
7 (46.7) 
5 (33.3) 
 
 
0.736 
Lymphatic/vascular space 
invasion  
39 (54.9) 8 (53.3) > 0.999 
Tumor location 
     Corpus 
     Lower uterine segment 
 
70 (97.2) 
2 (2.8) 
 
14 (93.3) 
1 (6.7) 
 
0.437 
Largest Median Tumor 
Dimension (cm) 
 
4 
 
3.5 
 
0.547 
1EC, endometrial cancer 
2CRC, colorectal cancer 
3FIGO stage I and II denote endometrial carcinomas confined to the uterus.  FIGO stages III   
 and IV represent extra-uterine spread of tumor. 
4Depth of myometrial invasion ≥ 50% total myometrial thickness is associated with increased   
     risk of lymph node metastasis 
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Specific Aim 3. Simplified Cost Analysis 
 Based on the data presented in Tables 5-9, it was determined that universal tumor 
testing identified the greatest number of PLS EC cases.  However, tissue testing of all 
patients could be a cost-prohibitive process.  To investigate this further, a simplified cost-
effectiveness analysis was performed using the cohort of 412 endometrial cancer patients.  
 SGO Criteria were applied to the unselected cohort of 412 EC cases, identifying 
97 women meeting criteria for further evaluation through tissue testing and genetic 
counseling, resulting in a total cost of $93,529.08 (Figure 12, Table 14).  Of these 97 
identified by the SGO model, 15 are PLS as defined by tissue testing.  The total cost per 
PLS case detected in the SGO model was $6,143.21.  It is estimated that 4-11 of these 15 
PLS cases would have a germline mutation detected based on germline mutation 
detection rates among those with positive tumor testing results of 25-75%.   
 The average number of FDRs for those meeting SGO criteria was 5.3.  Based on 
this and the range of estimated germline mutation rates among PLS EC cases, 21-48 
FDRs would be eligible for single site gene mutation analysis and enhanced LS 
screening.  The estimated costs for screening both PLS cases and their FDRs in this 
strategy is $3,055.46-$6,423.55 per case based on germline detection rates of 25-75% 
(Table 14). 
 Applying the universal tumor testing model identified 43 EC patients warranting 
further work-up through genetic counseling and germline testing (Figure 13).   The total 
cost of this screening strategy was $256,726.36, with cost per PLS case identified of 
$5,970.38.  It is estimated that 11-32 of these 43 patients would have a positive germline 
mutation (Table 14). 
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 The average number of FDRs for those included in the universal tumor-testing 
model was 5.5.  Based on this and the range of estimated germline mutation rates among 
PLS EC cases, 60-176 FDRs would be eligible for single site gene mutation analysis and 
enhanced LS screening.  The estimated costs for screening both PLS cases and their 
FDRs in this strategy is $3,003.35-$6,526.52 per case based on germline mutation 
detection rates of 25-75% (Table 14). 
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Figure 12.  Cost analysis schema utilizing SGO 5-10% Clinical Criteria as a screening 
model. 
 
1. GC, Genetic Counseling 
2. PLS, Probable Lynch Syndrome 
3. There was one case in which MLH1 promoter methylation did not work and this was included in the 
cases that would go on to receive genetic counseling and germline testing.
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Figure 13.  Cost analysis schema utilizing universal tumor testing via 
immunohistochemistry and MLH1 methylation analysis when indicated 
 
1. GC, Genetic Counseling 
2. PLS, Probable Lynch Syndrome 
 
*  There were three cases in which MLH1 methylation was unsuccessful.  One case met clinical referral 
criteria and was included in genetic counseling decision tree costs; the other two cases had no risk factors 
for LS and were not included in the genetic counseling costs with this model. 
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Table 14.  Comparison of direct Medicare costs associated with SGO Criteria and 
universal tumor testing models. 
 
 SGO Universal 
Endometrial Cancer Cases (N = 412)   
# pts who undergo IHC testing 97 412 
   
# pts who have loss of expression of IHC 21 118 
   
# pts who undergo MLH methylation testing 
 
# pts seen by genetic counselor 
13 
 
97 
90 
 
43 
   
# PLS identified by strategy 15 43 
   
# PLS estimated to have positive germline test  
(Detection rates of 25%, 50%, and 75% germline detection) 
 4, 8, 11 11, 22, 32 
Estimated Costs for Screening Strategies   
Cost to Screen 412 EC Cases $93,529.08 $256,726.36 
   
Average cost per PLS case detected $6,235.27 $5,970.38 
First degree relatives (FDRs)   
# FDRs eligible for germline testing if 25%, 50%, or 75% of 
PLS cases have an identifiable germline mutation 
 
21, 42, 58 60, 121, 176 
Assuming 50% of PLS cases have an identifiable germline 
mutation: 
     # of FDRs who will be germline positive for LS if 25%,    
     50% or 75% inherit the same mutation 
 
11, 21, 32 
 
30, 61, 91 
Estimated Costs For Screening Including both PLS and 
FDRs (Assuming 50% of PLS have germline mutation)   
 
Cost per LS case identified if 25% of FDRs have positive  
germline mutation: 
$6,432.55 $6,526.52 
   
Cost per LS case identified if 50% of FDRs have a positive 
germline mutation: $4214.43 $4,088.90 
   
Cost per LS case identified if 75% of FDRs have a positive 
germline mutation: $3,055.46 $3,003.35 
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 Next, we calculated the incremental cost effectiveness ratio (ICER) using both 
MD Anderson Cancer Center Costs and Medicare costs (Table 15).  The calculations 
assumed that 50% of PLS patients tested would have a germline mutation detected and 
varied the number of FDRs having an identifiable germline mutation between 25-75%.  
Comparing SGO Criteria to no screening at all, the ICER using Medicare costs vary  
between $3,055.46/LS case (assuming 75% of FDRs are germline positive) and 
$6,432.55/LS case (assuming 25% of FDRs will be germline positive). Using MD 
Anderson costs, the ICERs vary between $3,202.67/LS case and $6,742.46/LS case.  The 
SGO Criteria model costs an additional $3,000-$7,000 more per LS case identified than 
doing no screening at all. 
 Comparing the universal testing model to SGO Criteria, the ICER using Medicare 
costs vary between $2,974.89-$6,580.62/LS case, and the MD Anderson costs vary 
between $2,859.95-$6,326.56 /LS case.  This means that universal testing costs an 
additional $2,800-$6,600 more per LS case than using SGO Criteria.   
There is not a universally accepted ICER value that is interpreted as a favorable or 
unfavorable value. The ICER is one component of many factors that a health care 
administrator or provider can use to determine which intervention strategy would work 
best for his/her practice.  In this cohort, one could choose to utilize the SGO criteria 
model and spend $2,859.95-$6,326.56 per LS case to identify 4-11 germline Lynch 
Syndrome mutations in a population of 412 EC cases and potentially impact 21-58 FDRs.  
For an additional $2,800-$6,600 investment per LS case identified in the universal tumor 
testing model, 11-32 germline Lynch Syndrome mutations would be identified and 60-
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176 FDRs could be impacted.  This type of information can help to determine which 
strategy best benefits the specific patient population being examined. 
 
  
 
74
      Table 15.  Incremental cost effectiveness ratios (ICER) using direct MDACC institutional costs and direct Medicare costs. 
 # LS cases 
identified 
(pts + FDRs) 
MDACC Costs 
($) 
MDACC ICER 
$/case 
Medicare Costs 
($) 
Medicare 
ICER, $/case 
If 75% of FDRs have 
positive germline tests 
     
   No screening 0 $0 $0/case $0 $0/case 
   SGO screening 40 $122 $3,202.67 $122,218.44 $3,055.46 
   Universal screening 113 $336,883.14 $2,859.95 $339,379.04 $2, 974.80 
If 50% of FDRs have 
positive germline tests 
     
   No screening 0 $0 $0/case $0 $0/case 
   SGO screening 29 $128,106.68 $4,417.47 $122,218.44 $4,214.43 
   Universal screening 83 $336,883.14 $3,866.23 $339,379.04 $4,021.49 
If 25% of FDRs have 
positive germline tests 
     
   No screening 0 $0 $0/case $0 $0/case 
   SGO screening 19 $128,106.68 $6,742.46 $122,218.44 $6,432.55 
  Universal screening 52 $336,883.14 $6,326.56 $3339,379.04 $6,580.62 
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Discussion 
Endometrial Cancer Patient Population 
The EC population used for this study is derived from a large NCI designated 
cancer center so there exists a potential for referral bias.  However, published data from a 
large, national epidemiologic analysis of 161,513 EC cases show that the MDACC EC 
population is comparable in terms of baseline clinicopathologic characteristics (59).  
Table 16 shows selected characteristics including the number diagnosed at age < 50, 
endometrioid histology, and early stage disease between our population and the overall 
U.S. population.  The greatest difference between the two groups is that there is a higher 
proportion of women with grade 2 and 3 tumors in the MDACC population.  Despite 
these differences, there are no published data stating that Lynch Syndrome associated 
endometrial tumors occur preferentially within a certain grade of tumor, so it is 
reasonable to believe that the MDACC data can be generalized to other endometrial 
cancer patient populations. 
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Table 16. Clinicopathologic data of EC Cases for MD Anderson Cancer Center   
and U.S. Population. 
 
 MDACC 
% of EC 
population 
U.S. Population1 
% of EC 
population 
Diagnosed at age < 50 
 
15.2 13.9 
Histology 
     Endometrioid 
     Non-endometrioid 
 
82.4 
17.6 
 
85.3 
14.7 
Grade 
     1  
     2 
     3 
 
12.3 
61.0 
26.7 
 
48.7 
35.8 
16.1 
Stage2 
     I  
     II - IV 
 
72.8 
27.2 
 
74.7 
25.3 
1
 Derived from reference (59) 
2Data from reference (57) was derived from the SEER database, in which staging is  
recorded using the local/regional/distant categories. MDACC surgical staging data is   
according to the FIGO staging system. FIGO Stage I and SEER “Local” category both refer  
to disease limited to the uterus.  Direct comparisons cannot be made for other FIGO stages. 
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In addition to having comparable overall EC demographics, the results of the 
immunohistochemical and MLH1 analyses are comparable to both national and 
international published data.  A study by Backes et al. involved performing 
immunohistochemical analysis for expression of MLH1, MSH2, MSH6, and PMS2 on all 
tumors in a series of 140 unselected, endometrial cancers. Tumors with intact nuclear 
staining were considered sporadic, and tumors with absent MSH2 and/or MSH6 were 
referred for genetic counseling. MLH1 promoter methylation analysis was not performed. 
For patients with tumors exhibiting loss of MLH1 and/or PMS2, those diagnosed at age > 
60 years and no FDRs with endometrial or colorectal cancer received no further follow 
up, and those younger than age 60 years or having FDRs with EC or CRC received 
referral for genetic counseling.  Their study showed that 21.4% of all EC tumors 
exhibited IHC nuclear loss of at least one MMR protein (60).  A similar, population-
based study was undertaken by Leenen et al.in which 183 sequential, unselected EC 
tumors of women diagnosed at ≤ 70 years underwent both MSI and IHC testing.  
Individuals with MSI-H tumors and absent IHC expression of MSH2, MSH6, or PMS2 
were referred for genetic counseling. MSI-H tumors with IHC loss of MLH1 underwent 
MLH1 methylation analysis, and those with absent methylation were referred to genetic 
counseling.  Their study found a rate of 23.5% of IHC loss among all EC tumors, and 
96.9% of tumors with IHC loss of MLH1 were methylated (34). A summary of these 
published findings, including data from our study, are summarized in Table 17.  These 
findings support the idea that the results of this thesis research are potentially 
generalizable to other endometrial cancer patient populations. 
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Table 17.  Comparison of MD Anderson results to similarly designed, population-based 
endometrial cancer national and international studies. 
 
 MDACC1 
N = 408 
Ohio State2 
N = 140 
Netherlands3 
N = 179 
% IHC Loss 
 
28.9 21.4 23.5 
% MLH1 Loss 
 
22.0 17.1 17.9 
% methylated 
MLH1 promoter 
 
82.7 Not performed 96.9 
% with PLS EC 
 
10.5 Estimate (7.7)4 6 (3-11) 
1: MDACC: MD Anderson Cancer Center 
2: (60) 
3: (34) 
4: Ohio State calculation of % PLS is based on an approximate 80% methylation rate of tumors with IHC 
loss of MLH1. 
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SGO Clinical Criteria 
 Society of Gynecologic Oncology clinical screening criteria for Lynch Syndrome 
among endometrial cancer patients was codified in 2007.  As can be seen from Tables 1 
and 2, these criteria strongly resemble Amsterdam II and revised Bethesda Guidelines. 
Thus, many of the clinical recommendations for identifying endometrial cancer patients 
at elevated risk for having Lynch Syndrome have been extrapolated from colorectal 
cancer registries.  
 Ryan et al. evaluated Amsterdam II, revised Bethesda, and SGO criteria in a 
cohort of 76 endometrial cancer cases with known Lynch Syndrome germline mutations 
identified through databases from the British Columbia Familial Cancer Registry and 
Mount Sinai Hospital Familial Gastrointestinal Cancer Registry.  They found that SGO 5-
10% criteria identified 93% of EC cases with known germline mutations.  The detection 
rates of MLH1, MSH2, and MSH6 using SGO 5-10% criteria were 94%, 94%, and 88%, 
respectively. There were no PMS2 mutations in this patient population. They concluded 
that SGO 5-10% Criteria performed best in identifying germline Lynch Syndrome 
mutations in endometrial cancer cases (13).  These criteria have not been validated in 
either a clinic-based referral population or a population-based setting. 
 The predominance of MLH1 and MSH2 mutation carriers within Lynch Syndrome 
registries, including the three in which mutation carriers from the Ryan et al. study were 
derived, results in validation of existing criteria for these types of mutations. The relative 
paucity of MSH6 and PMS2 mutation carriers in Lynch Syndrome registries suggests that 
these mutations are rare or that they are missed by current screening strategies.  Work by 
Senter and colleagues investigated 99 individuals with immunohistochemical loss of 
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PMS2 in 99 Lynch Syndrome associated tumors (91 CRC, 5 EC, 1 gastric, 1 small bowel, 
and 1 transition cell of renal pelvis) and performed PCR-based mutation analysis.  Cases 
were obtained both through clinic-based screening criteria as well as in the population-
based setting; 8/99 (8.1%) were endometrial cancers.  They found that 62% of cases with 
IHC loss of PMS2 had a detectable PMS2 germline mutation.  Among germline carriers, 
9.1% met Amsterdam II guidelines, 65.5% met revised Bethesda Guidelines, and 25.5% 
met no published clinical criteria (58).  The fact that only a quarter of germline PMS2 
mutation carriers meet published clinical guidelines supports the possibility that its 
prevalence in Lynch Syndrome associated cancers may be under-estimated.   
 Published data on cumulative cancer risk to age 70 among individuals with known 
germline MSH6 mutations have been shown to be less than that for MLH1 and MSH2 
mutations carriers (61).  Hendriks et. al examined the lifetime cancer risks among 146 
individuals with germline mutations in MSH6 who met Amsterdam II criteria, compared 
to a cohort of MLH1 and MSH2 germline mutation carriers.  For male MSH6 mutation 
carriers, the cumulative colorectal cancer risk is 69%; for female MSH6 mutation carriers, 
the cumulative colorectal cancer risk is 30% and the cumulative risk for endometrial 
cancer is 70%.  Additional clinical screening criteria were not evaluated in their study, 
but MSH6 mutations carriers have been found to not meet standard clinical criteria in 
several previously published studies (62,63).  
 The performance of SGO Criteria in our population of identifying individuals at 
elevated risk (IHC loss of MLH1, MSH2, MSH6 or PMS2 with absence of MLH1 
promoter methylation) is consistent with these other published results.  Clinical criteria 
perform best at detecting those with IHC loss of MLH1 or MSH2, but perform quite 
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poorly at identifying those with loss of MSH6 or PMS2.  Based on the findings of our 
study and other published literature, clinical criteria preferentially identify only a subset 
of patients with endometrial cancer at risk for having Lynch Syndrome. 
 The underlying cause for an older median age at diagnosis for MSH6 or PMS2 
mutations has not been elucidated.  Work by Chen and colleagues examined single 
nucleotide polymorphisms (SNPs) of genes playing key roles in the cell cycle in a 
population of individuals with identifiable germline Lynch Syndrome mutations 
identified through a CRC registry.  They utilized CART analysis and found that certain 
SNPs were associated with either earlier median onset of CRC diagnosis or a later age of 
onset.  One SNP association they found associated with older age at diagnosis was 
individuals with wildtype E2F2 and AURKA variant had a median age of diagnosis of 70 
(64).  It is possible that genetic variants may also play a role in endometrial cancers in 
individuals harboring MSH6 and PMS2 mutations that might explain the older median 
age at diagnosis in this subgroup. 
 In the colorectal cancer literature, there have been modifier genes identified that 
may account for some of the variability seen among germline Lynch Syndrome mutation 
carriers.  Wijnen and colleagues explored the role of established SNPs associated with 
CRC (8q24.21, 18q21.1, 15q13.3, 8q23.2, 10p14, and 11q23.1) in a population of 675 
patients with germline Lynch Syndrome mutations. They found that an individual with 
either the SNP rs3802842 (11q23.1) or rs16892766 (8q23.3) as well as a germline Lynch 
Syndrome mutation had a greater risk for developing CRC than individuals without these 
SNPs (65).  This work was validated by Talseth-Palmer et al. in a cohort of 684 
individuals with confirmed germline mutations in Lynch Syndrome genes.  They found 
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the association between the SNPs on 11q23.2 and 8q23.2 was valid for only those with 
MLH1 mutations (66).  Talseth-Palmer et al. subsequently performed a combined 
analysis of data derived from the Wijnen et al. and Talseth-Palmer et al. studies to further 
characterize the role of these SNPs among MLH1 germline mutation carriers.  Among 
individuals with Lynch Syndrome, they found the SNP at 11q23.1 was associated with an 
increased CRC risk compared to individuals without Lynch Syndrome.  Additionally, 
Lynch Syndrome mutation carriers with the SNP at 8q23.2 were diagnosed at earlier ages 
(67).  These studies call attention to modifier genes and their impact on the variability 
seen within colorectal cancer among Lynch Syndrome patients.  There are currently no 
published studies examining the role of modifier genes among the endometrial cancer 
cases in patients with Lynch Syndrome. 
SGO Clinical Criteria among Endometrial Cancer Patients with IHC loss of MLH1 
 Approximately 15-20% of all endometrial and colorectal tumors will exhibit IHC 
loss of MLH1; however, between 60-90% of these tumors are considered sporadic rather 
than hereditary because they have epigenetic silencing of the MLH1 promoter through a 
methylation event (26-28,30). Despite the body of research that supports performing the 
PCR-based MLH1 methylation assay when evaluating tumors exhibiting IHC loss of 
MLH1, it is not routinely performed in the published literature describing clinical 
screening algorithms for LS (33-36).  Though the reasons for this are not entirely clear, 
one possible explanation could be that some clinical laboratories do not have access to 
PCR-based testing or only have access to simpler PCR analyses such as hot-spot 
sequencing for mutational analyses. 
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This sub-analysis was designed to determine if any clinical, pathologic, or clinical 
screening tool could effectively replace using the PCR-based MLH1 methylation analysis 
in the evaluation of endometrial cancer patients for possible Lynch Syndrome. Therefore, 
our evaluation was limited to ECs with loss of MLH1 in our convenience sample cohort. 
From the data presented in Tables 10-13, we conclude that no combination of clinical, 
pathologic, or clinical criteria is superior to MLH1 methylation in evaluating tumors with 
IHC loss of MLH1.  
Several published reports support that the prevalence of MLH1 methylation 
increases with age (31,32).  An investigation by Whelan et al. examined 40 endometrial 
carcinomas with immunohistochemical loss of MLH1 and compared their 
clinicopathologic information to 40 endometrial carcinomas with intact MLH1. It is 
unclear if their endometrial cases were recruited from a population-based setting or from 
a clinic-based referral population.  They found a significant difference between the age of 
endometrial cancer diagnosis in MLH1 methylated (mean age 56.1 years) versus 
unmethylated (mean age of 65.4 years) cases (31).  Work by Zauber and colleagues also 
investigated MLH1 methylation in the endometrial cancers, examining differences 
between women diagnosed at less than age 50 compared to women diagnosed at greater 
than or equal to age 50.  They found that 61.9% of MSI-H tumors were unmethylated in 
the younger group with a median age of diagnosis of 42.6, and 17.1% of MSI-H tumor 
were unmethylated in the older group with a median age of diagnosis of 64.6.  As can 
been seen in tables 10 and 13, we found no statistically significant difference in either our 
convenience sample cohort or population-based cohort in terms of median age of 
diagnosis between methylated and unmethylated MLH1 EC tumors.  Our data agree with 
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other published data that MLH1 methylation of EC tumors increases with increasing age, 
but age does not accurately predict methylation status. 
Previous investigators have demonstrated that there are macroscopic and 
microscopic pathologic features of endometrial carcinomas that correlate with a diagnosis 
of Lynch Syndrome. Westin et al. examined endometrial carcinomas arising from the 
lower uterine segment (LUS) and found that 29% (10/35) were Lynch Syndrome-
associated (44).  Among these 10 cases, 9/10 had loss of MSH2 by IHC and 1 had loss of 
MLH1 without MLH1 methylation. In both our convenience sample and population-
based cohorts, LUS tumor location did not distinguish between the methylated and 
unmethylated MLH1 tumors with IHC loss of MLH1.  
When immunohistochemistry for DNA mismatch repair proteins is used as part of 
the evaluation for Lynch Syndrome in endometrial or colorectal cancers, absence of 
MLH1 immunohistochemical protein expression is a poor predictor for a germline 
mutation (38), as most of these tumors will also have somatic methylation of the MLH1 
gene (sporadic carcinoma), rather than germline mutation (Lynch Syndrome).  Further, 
our sub-analysis supports that clinical and pathologic screening criteria poorly predict 
which endometrial cancers with IHC loss of MLH1 are likely to have presence or absence 
of MLH1 methylation. In our convenience sample cohort of 54 endometrial cancer cases 
with immunohistochemical loss of MLH1, 14/54 cases would be candidates for germline 
MLH1 testing.  SGO criteria correctly identifies 10/14 unmethylated tumors.  If SGO 
criteria were solely used without the MLH1 methylation assay, 22/54 patients would 
undergo germline testing for MLH1, thereby subjecting 12 women to unnecessary and 
expensive germline testing.  We conclude that MLH1 promoter methylation testing is a 
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valuable component of clinical laboratory tumor testing for Lynch Syndrome among 
patients with endometrial cancers exhibiting immunohistochemical loss of MLH1. 
Historical Risk Factors for Lynch Syndrome and Generation of New Criteria 
 From the data presented in this thesis, historically accepted risk factors such as 
young age at cancer diagnosis, strong family history, and non-obese BMI (< 30 kg/m2) 
are not as useful at delineating sporadic endometrial cancer from Lynch Syndrome 
associated cases.  Several studies have shown that the prevalence of Lynch Syndrome due 
to defects in all DNA MMR genes is increased in women diagnosed with endometrial 
cancer at age younger than 50 years.  In the study by Lu et al., 11% (11/100) of women 
presenting with endometrial cancer at age younger than 50 years had tumor testing results 
suggestive of Lynch Syndrome and 9% had an identifiable germline mutation. Of the 9 
women with identifiable germline mutations, 7 had an MSH2 mutation, 1 had an MLH1 
mutation, and 1 had an MSH6 mutation (56).  In a similar study performed by Walsh et 
al., 18% (26/146) of women with endometrial cancer diagnosed at less than age 50 years 
had molecular diagnostics testing (IHC, MSI, and MLH1 methylation) consistent with 
Lynch Syndrome. In their study, there were 6 MLH1 13, MSH2, and 7 MSH6 PLS 
tumors. In both of these studies, those with presumed MSH2 mutations were the most 
likely to present with Lynch Syndrome associated endometrial cancer at a younger age 
(68).  
Obesity is an important determinant of endometrial cancer risk in the sporadic 
patient population (69).  The relationship between BMI and Lynch Syndrome associated 
endometrial cancer has been investigated previously in patients younger than age 50 as 
well as in cohorts consisting of all ages.  Lu et al. found that a median BMI of 27.6 
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among Lynch Syndrome endometrial cancer cases was significantly lower than the 
median BMI of 37.5 among sporadic cases in a set of EC patients diagnosed at age less 
than 50.  The sensitivity and specificity of BMI ≤ 30 for predicting Lynch Syndrome was 
56% and 65%, respectively (56).  Another study by Schmeler et al. found that 56% of 
188 EC patients under the age of 50 were obese (BMI ≥ 30.0), and all six patients with 
Lynch Syndrome were either normal weight or overweight (BMI 25.0-29.9) (70).  In one 
additional study, McCourt et al. evaluated microsatellite instability in a series of 473 
sequential endometrial carcinomas and found that patients with MSI-high tumors had a 
significantly lower BMI (30.3) than those with microsatellite-stable tumors (32.7) (29).  
While these studies support that BMI may play a role in differentiating between sporadic 
and Lynch Syndrome associated endometrial tumors, the results from our study reveal no 
statistically significant difference between BMI < 30 and a diagnosis of PLS EC.  This 
could be due in part to the increases in obesity in the U.S. population, which may obscure 
a previously significant differentiator between sporadic and Lynch Syndrome associated 
tumors. Also, the median age of EC diagnosis in our unselected patient cohort was well 
above 50 (age 61).  It is possible that BMI is a distinguishing feature only in younger EC 
patients. 
A strong family history of certain cancers played a pivotal role in the initial 
identification and characterization of Lynch Syndrome and continues to be a principal 
component in widely accepted clinical screening algorithms such as Amsterdam II, 
revised Bethesda guidelines, MMRPro, PREMM, MMRPredict, and SGO Criteria.  
Unfortunately, family history is not perceived to be as helpful as it once was.  In 2009, 
the EGAPP working group de-emphasized the role of family history when evaluating 
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individuals for risk of Lynch Syndrome, recommending a universal tumor testing 
approach.  This recommendation was due in part to the poor overall sensitivity and 
specificity profiles of clinic-based screening criteria such as Amsterdam II or Revised 
Bethesda guidelines as well as suboptimal recording patient history by clinicians (46).  
We found no statistically significant differences in family history of EC or CRC between 
our PLS EC cases and sporadic EC cases.  Further, the majority of all patients in our 
cohort did not have a family history of either tumor. Additionally, average family size in 
the 2000sis not the same as it was when Lynch Syndrome was first characterized in the 
early 1900s.  In Dr. Warthin’s original Family G, there was a male proband with 10 
children.  In our current cohort, the average number of siblings among our endometrial 
cancer cases was 3.4, and the average number of children was 2.1.  As family sizes 
decrease, the probability of detecting a high proportion of cancers also decreases.  The 
utility of family history in identifying patient’s at risk for hereditary cancer syndromes 
may be decreasing in the current generations. 
Further analyses to modify SGO Criteria or generate new clinical criteria to better 
identify Lynch Syndrome among endometrial cancer patients could not be generated 
from our cohort of 408 cases.  In order to capture the maximal number of women with 
Lynch Syndrome who present with endometrial cancer, it may be necessary to adopt a 
universal tumor testing approach, as is increasingly being recommended for colorectal 
cancer patients. 
 
 
 
  
 
88
Cost Analysis 
 There are few published cost analyses that evaluate screening methodologies for 
Lynch syndrome in women presenting with endometrial cancer.  Kwon et. al evaluated 
several different screening strategies using a Monte Markov simulation model to evaluate 
the costs (IHC for DNA MMR genes, genetic counseling, germline testing, colonoscopy 
for detected LS cases, and average lifetime cost of CRC treatment) relative to the benefits 
(life expectancy) and generated an ICER for each screening strategy.  They found that 
triaging all women with endometrial cancer who had a first-degree relative having a 
Lynch Syndrome-associated cancer at any age with immunohistochemistry was the most 
cost effective method (33).  If we were to apply this screening strategy to our existing 
population-based cohort of 412 EC cases, 60 (14.6%) individuals would undergo 
immunohistochemical analysis, with 9 of these having tumor testing suggestive of Lynch 
Syndrome.  This leaves 34 individuals with tumor testing consistent with Lynch 
Syndrome that would go undiagnosed using the Kwon et. al screening strategy.  Though 
determined cost effective by Kwon’s analysis, one must determine if the cost savings is 
worth the potential health-related implications of missing the diagnosis in 34 individuals 
and the impact this might have on both them and their first-degree relatives. 
 Work by Dinh and colleagues thoroughly evaluated screening strategies for 
colorectal and endometrial cancer using a Monte Carlo simulation of 100,000 
hypothetical individuals modeled after the U.S. population starting at age 20.  They 
compared direct medical costs for risk-assessment based screening (PREMM1,2,6) starting 
at different age at diagnosis and compared this to universal 4-gene mutation sequencing 
of all individuals.  Unique to their study, they evaluated an individual’s risk prior to the 
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development of EC or CRC and the detection/prevention of these cancers was also 
incorporated in to costs/benefits. They found that risk-assessment of all individuals 
between the ages of 25-35 with PREMM1,2,6 followed by genetic testing for those with a 
risk score of ≥ 5 % was the most cost-effective strategy (71).  At the time of this 
publication, the study by Mercado et al evaluating the PREMM1,2,6, MMRPro, and 
MMRPredict algorithms in endometrial cancer had not yet been published.  Dinh’s study 
utilized PREMM1,2,6 as its sole risk-assessment strategy and found it to have an area 
under the curve (AUC) of 0.77; an AUC greater than 0.80 is deemed favorable.  None of 
these screening strategies have been validated in the PMS2 germline mutation population. 
 In our analysis, the cost per PLS case identified using a universal tumor testing 
strategy comprised of immunohistochemistry and MLH1 methylation analysis when 
indicated is $5,970.38.  While this could be considered a favorable cost, creating an ideal 
cost analysis strategy is difficult. As can be seen by both our work and the work from 
others described above, there can be immense shift in costs as different assumptions and 
costs are added or removed from the models.  The variation in perspective from different 
physician groups, different cancer patient populations, and different societies can also 
influence how such cost analyses are perceived.   
Compliance with Published Screening Criteria Guidelines 
 As we strive to identify the best model for identifying Lynch Syndrome among 
endometrial cancer patients, it is important to be aware of the compliance of physicians 
with meeting referral guidelines.  In our analysis, only 30% of endometrial cancer 
patients meeting institutional referral criteria actually received a recommendation to see a 
genetic counselor.  This low rate is comparable to other published studies examining 
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compliance with screening recommendations.  In the BRCA population, Meyer et al. 
examined the medical records of 3,765 ovarian cancer patients, of which 23.8% were 
determined to be at substantial risk for having a BRCA mutations.  Only 12% of these 
patients were referred to genetic counseling at the beginning of their study, and this 
number increased to 48% following a clinic-based intervention strategy.  Despite a 
dramatic improvement in referral habits over the course of the study, 50% of women at 
substantial risk were not offered genetic counseling at the end of the study period (72).  
Grover et al. evaluated the genetic counseling referral rate among colorectal cancer 
patients who met revised Bethesda Guidelines.  In their cohort of 387 patients, 75 (19%) 
met referral criteria, but only 13 (17%) of these patients received a referral for genetic 
counseling and further risk assessment (73).  
 These data, coupled with results from our analysis, show a very poor compliance 
with published hereditary cancer syndrome screening guidelines.  If published guidelines 
have excellent sensitivity and specificity for detecting disease, it would seem reasonable 
to create systems within the clinic-based setting to improve history-taking and referral 
rates.  In the case of SGO Criteria, it may not be as beneficial to invest resources in 
improved referral when only a 32% of patients at elevated risk are identified.  There has 
been one study in the CRC literature examining referral rates after implementation of a 
universal tumor testing regimen comprised of microsatellite instability testing and 
immunohistochemistry in all CRC cases.  Heald and colleagues evaluated three different 
referral programs: 1) test results were sent only to the surgeon; 2) test results went to both 
the surgeon and genetic counselor, and the genetic counselor would send a follow up e-
mail to the surgeon; and, 3) test results went to both the surgeon and genetic counselor, 
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and the genetic counselor would contact the patient and arrange a follow-up appointment.  
They found that the multidisciplinary approach (Options 2 and 3) resulted in 10-fold 
quicker follow-up for patients when compared to a single individual approach (Option 1).  
When the genetic counselor was the primary point of patient follow-up (Option 3), 100% 
of patients meeting referral criteria received a referral, whereas only 55% of those in 
Option 1 and 82% of those in Option 2 received a referral (47). 
Study Limitations 
 This study has several limitations.  First, it is a retrospective study and all 
clinicopathologic data was abstracted from the electronic medical record.  This 
particularly affects acquisition of family history.  Ideally, a full 3-generation family 
history is obtained from a genetic counseling professional and patient’s fulfillment of 
clinical screening criteria is based on that assessment.  Many patients have recall bias or 
vague ideas of the original location of a family member’s tumor.  For example, they 
know that a family member had a gynecologic cancer but unsure of whether it was cervix, 
uterine, or ovary. Our study delineated whether or not a patient met criteria based on self-
reported history and genetic counseling data when available. 
 Additionally, we have based our assessment of SGO Criteria on its ability to 
detect elevated-risk EC tumors defined by those with IHC loss of a DNR MMR protein 
(absence of MLH1 methylation when indicated) and not on its ability to detect germline 
mutations.  At this point in time, patients have been notified of their tumor testing results 
and are in various stages of genetic counseling follow-up.  Many previously published 
studies have used germline testing results as the “gold” standard.  DNA sequencing is 
known for high sensitivity in detecting point mutations and small insertions, but the large 
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deletions, insertions, or gene arrangements are not as easily detected (48).  Thus, when a 
patient has tumor molecular diagnostic testing results suggestive of LS but negative 
germline testing, the question remains whether or not that patient truly has Lynch 
Syndrome.   
 Of the myriad of studies using molecular diagnostics testing to evaluate for Lynch 
Syndrome, there is only one publication that addresses tumor test positive/germline 
negative cases.  Rodriguez-Soler et al. evaluated 1,705 consecutive colorectal patients for 
Lynch Syndrome by performing MSI and IHC testing on all tumors (74).  They examined 
clinicopathologic data of patients as well as age-adjusted incidence of cancer in family 
members between sporadic, tumor test positive/germline negative, and germline positive 
individuals. They found that germline positive patients were more likely to fulfill revised 
Bethesda guidelines than the tumor test positive/germline negative.  Additionally, they 
found that the familial incidence of colorectal cancer was greatest in germline mutation 
carriers, next highest in tumor test positive/germline negative, and least in families with 
an individual with a sporadic colorectal cancer.  Risk of endometrial cancer and other 
Lynch Syndrome associated tumors were not included in this study.  More investigation 
needs to be done to determine the optimal approach to managing tumor test 
positive/germline negative patients, particularly since published guidelines support 
universal tumor testing of all colorectal cancers. 
 Lastly, the assumptions built in to our simplified cost analysis help to generate an 
estimate of direct costs, but it does not encompass many other factors that can be part of 
costs/benefits of any healthcare decision. To begin with, our model assumes a 100% 
genetic counseling referral rate for endometrial cancer patients meeting SGO Criteria, 
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when published rates for various criteria in clinical practice vary from 17-48%.  Thus, 
costs associated with the SGO model are a higher estimate than what would likely occur 
in reality (72,73).  Our model also assumes that all patients either meeting SGO Criteria 
or with tumor testing suggestive of Lynch Syndrome will accept referral for genetic 
counseling and/or germline testing.  Compliance of endometrial cancer patients with 
genetic counseling referrals to evaluate for Lynch Syndrome may not be 100%.  In a 
single institution study, Backes and colleagues surveyed the 47/384 EC patients who met 
institutional criteria for genetic counseling referral through a mailed questionnaire and 
follow-up phone call. Immunohistochemistry was performed on all endometrial cancers 
and referral for genetic counseling was recommended for: 1) individuals with loss of 
MLH1/PMS2 diagnosed at less than age 60; 2) individuals with loss of MLH1/PMS2 
with a family history of a Lynch Syndrome associated tumor in a first-degree relative; 3) 
any individual with loss of MSH2/MSH6, MSH6 only, or PMS2 only.  A total of 26/47 
(55.3%) responded to the questionnaire and 20/26 (77%) stated that they had been 
referred to see a genetic counselor.  Despite referral, only 9/20 (45%) saw a genetic 
counselor and 8/9 underwent germline testing.  They found the two most common 
reasons for not seeing a genetic counselor were lack of insurance/cost for seeing a genetic 
counselor and anxiety related to the results (75). 
 There are many more costs that can be incorporated into a cost analysis, such as 
the cost of more frequent colonoscopy in LS cases, cost of colonoscopy complications, 
the cost of failing to prevent a colorectal cancer in an undetected LS case, the cost of a 
preventable EC or CRC in first-degree family members, and the emotional “cost” 
associated with the anxiety of testing.  There are also different measures of effectiveness 
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that could be used such as number of cancers prevented or cancers diagnosed at an early 
stage.  Referring to Figure 4, it is easy to see how subtle changes in the assumptions and 
inputs into the model can cause more dramatic changes in ICER, our metric for cost 
effectiveness comparison.  Lastly, costs for this analysis were calculated using 2012 U.S. 
dollars and 2012 CPT codes.  Inflation, CPT codes, and Medicare reimbursements can all 
change year to year.  Therefore, rather than focusing on absolute costs, for our cost 
analysis it is more useful to consider the relative cost between the SGO screening method 
and the universal tumor testing method.  
Conclusions 
This is the first large, single-institution study examining endometrial cancer and 
Lynch Syndrome in a population-based fashion with a universal testing model starting 
with immunohistochemical analysis of all endometrial tumors.  Our evaluation of the 
Society of Gynecologic Oncology 5-10% Clinical Criteria’s ability to detect probable 
Lynch Syndrome endometrial cancer cases has shown that SGO Criteria identify only a 
small subset of PLS EC cases in the population-based setting.  Universal tumor testing of 
EC (IHC and MLH1 methylation when indicated) is a cost-effective alternative that 
detects more individuals at elevated risk, providing more opportunity for cancer 
prevention among women and their families. 
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